Medtronic (MDT) 10-Q 30 Aug 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jul. 26, 2019	Aug. 27, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 26, 2019
Document Transition Report	false
Entity File Number	001-36820
Entity Registrant Name	Medtronic plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1183488
Entity Address, Address Line One	20 On Hatch, Lower Hatch Street
Entity Address, City or Town	Dublin 2
Entity Address, Country	IE
Country Region	353
City Area Code	1
Local Phone Number	438-1700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Ordinary Shares Outstanding		1,341,669,471
Entity Central Index Key	0001613103
Amendment Flag	false
Current Fiscal Year End Date	--04-24
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Address, Postal Zip Code	D02 XH02
Ordinary shares, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value $0.0001 per share
Trading Symbol	MDT
Security Exchange Name	NYSE
Floating Rate Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2021
Trading Symbol	MDT/21
Security Exchange Name	NYSE
0.000% Senior Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2021
Trading Symbol	MDT/21A
Security Exchange Name	NYSE
0.000% Senior Notes due 2022
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2022
Trading Symbol	MDT/22B
Security Exchange Name	NYSE
0.375% Senior Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	0.375% Senior Notes due 2023
Trading Symbol	MDT/23B
Security Exchange Name	NYSE
0.25% Senior Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	0.25% Senior Notes due 2025
Trading Symbol	MDT/25
Security Exchange Name	NYSE
1.125% Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2027
Trading Symbol	MDT/27
Security Exchange Name	NYSE
1.625% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.625% Notes due 2031
Trading Symbol	MDT/31
Security Exchange Name	NYSE
1.625% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.00% Senior Notes due 2031
Trading Symbol	MDT/31A
Security Exchange Name	NYSE
2.250% Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	2.250% Notes due 2039
Trading Symbol	MDT/39A
Security Exchange Name	NYSE
1.50% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	1.50% Senior Notes due 2039
Trading Symbol	MDT/39B
Security Exchange Name	NYSE
1.75% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) Security	1.75% Senior Notes due 2049
Trading Symbol	MDT/49
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Income Statement [Abstract]
Net sales	$ 7,493	$ 7,384
Costs and expenses:
Cost of products sold	2,366	2,204
Research and development expense	587	585
Selling, general, and administrative expense	2,543	2,597
Amortization of intangible assets	440	446
Restructuring charges, net	47	62
Certain litigation charges	47	103
Other operating (income) expense, net	(22)	151
Operating profit (loss)	1,485	1,236
Other non-operating income, net	(101)	(186)
Interest expense	609	242
Income (loss) before income taxes	977	1,180
Income tax provision	100	103
Net income (loss)	877	1,077
Net income attributable to noncontrolling interests	(13)	(2)
Net income (loss) attributable to Medtronic	$ 864	$ 1,075
Basic earnings per share (usd per share)	$ 0.64	$ 0.79
Diluted earnings per share (usd per share)	$ 0.64	$ 0.79
Basic weighted average shares outstanding (shares)	1,340.8	1,352.7
Diluted weighted average shares outstanding (shares)	1,351.9	1,365.4

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 877	$ 1,077
Other comprehensive income (loss), net of tax:
Unrealized gain on investment securities	56	0
Translation adjustment	66	(824)
Net investment hedge	99
Net investment hedge		0
Net change in retirement obligations	13	27
Unrealized (loss) gain on cash flow hedges	(7)
Unrealized (loss) gain on cash flow hedges		213
Other comprehensive income (loss)	227	(584)
Comprehensive income including noncontrolling interests	1,104	493
Comprehensive income attributable to noncontrolling interests	(13)	(2)
Comprehensive income attributable to Medtronic	$ 1,091	$ 491

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Current assets:
Cash and cash equivalents	$ 5,080	$ 4,393
Investments	5,603	5,455
Accounts receivable, less allowances of $196 and $190, respectively	5,894	6,222
Inventories, net	3,932	3,753
Other current assets	2,196	2,144
Total current assets	22,705	21,967
Property, plant, and equipment	11,136	10,920
Accumulated depreciation	(6,425)	(6,245)
Property, plant, and equipment, net	4,711	4,675
Goodwill	40,082	39,959
Other intangible assets, net	20,234	20,560
Tax assets	1,545	1,519
Other assets	1,991	1,014
Total assets	91,268	89,694
Current liabilities:
Current debt obligations	1,458	838
Accounts payable	1,906	1,953
Accrued compensation	1,507	2,189
Accrued income taxes	500	567
Other accrued expenses	3,147	2,925
Total current liabilities	8,518	8,472
Long-term debt	24,804	24,486
Accrued compensation and retirement benefits	1,640	1,651
Accrued income taxes	2,873	2,838
Deferred tax liabilities	1,346	1,278
Other liabilities	1,590	757
Total liabilities	40,771	39,482
Commitments and contingencies (Note 17)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,340,797,328 and 1,340,697,595 shares issued and outstanding, respectively	0	0
Additional paid-in capital	26,470	26,532
Retained earnings	26,377	26,270
Accumulated other comprehensive loss	(2,484)	(2,711)
Total shareholders’ equity	50,363	50,091
Noncontrolling interests	134	121
Total equity	50,497	50,212
Total liabilities and equity	$ 91,268	$ 89,694

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 196	$ 190
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (shares)	1,340,797,328	1,340,697,595
Ordinary shares outstanding (shares)	1,340,797,328	1,340,697,595

Consolidated Statements of Equi

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions	Total	Total Shareholders’ Equity	Ordinary Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Beginning balance (shares) at Apr. 27, 2018			1,354,000,000
Beginning balance at Apr. 27, 2018	$ 50,822	$ 50,720	$ 0	$ 28,127	$ 24,379	$ (1,786)	$ 102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,077	1,075			1,075		2
Other comprehensive income (loss)	(584)	(584)				(584)
Dividends to shareholders	(677)	(677)			(677)
Issuance of shares under stock purchase and award plans (shares)			7,000,000
Issuance of shares under stock purchase and award plans	446	446		446
Repurchase of ordinary shares (shares)			(9,000,000)
Repurchase of ordinary shares	(820)	(820)		(820)
Stock-based compensation	64	64		64
Changes to noncontrolling ownership interests	1						1
Ending balance (shares) at Jul. 27, 2018			1,352,000,000
Ending balance at Jul. 27, 2018	$ 50,329	50,224	$ 0	27,817	24,730	(2,323)	105
Beginning balance (shares) at Apr. 26, 2019	1,340,697,595		1,341,000,000
Beginning balance at Apr. 26, 2019	$ 50,212	50,091	$ 0	26,532	26,270	(2,711)	121
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	877	864			864		13
Other comprehensive income (loss)	227	227				227
Dividends to shareholders	(724)	(724)			(724)
Issuance of shares under stock purchase and award plans (shares)			3,000,000
Issuance of shares under stock purchase and award plans	205	205		205
Repurchase of ordinary shares (shares)			(3,000,000)
Repurchase of ordinary shares	(328)	(328)		(328)
Stock-based compensation	$ 61	61		61
Ending balance (shares) at Jul. 26, 2019	1,340,797,328		1,341,000,000
Ending balance at Jul. 26, 2019	$ 50,497	$ 50,363	$ 0	$ 26,470	$ 26,377	$ (2,484)	$ 134

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Statement of Stockholders' Equity [Abstract]
Dividends to shareholders (usd per share)	$ 0.54	$ 0.50

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Operating Activities:
Net income	$ 877	$ 1,077
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	657	666
Provision for doubtful accounts	25	15
Deferred income taxes	18	3
Stock-based compensation	61	64
Loss on debt extinguishment	406	0
Other, net	58	3
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	319	138
Inventories, net	(122)	(180)
Accounts payable and accrued liabilities	(629)	85
Other operating assets and liabilities	(160)	(169)
Net cash provided by operating activities	1,510	1,702
Investing Activities:
Acquisitions, net of cash acquired	(145)	(104)
Additions to property, plant, and equipment	(301)	(291)
Purchases of investments	(1,669)	(982)
Sales and maturities of investments	1,569	2,020
Other investing activities	(5)	0
Net cash (used in) provided by investing activities	(551)	643
Financing Activities:
Change in current debt obligations, net	88	(505)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(5,035)	(12)
Dividends to shareholders	(724)	(677)
Issuance of ordinary shares	210	450
Repurchase of ordinary shares	(333)	(824)
Other financing activities	(47)	(5)
Net cash provided by (used in) financing activities	(274)	(1,573)
Effect of exchange rate changes on cash and cash equivalents	2	(61)
Net change in cash and cash equivalents	687	711
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	5,080	4,380
Cash paid for:
Income taxes	198	348
Interest	$ 86	$ 55

Basis of Presentation

Basis of Presentation	3 Months Ended
	Jul. 26, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019 . The Company’s fiscal years 2020 , 2019 , and 2018 will end or ended on April 24, 2020 , April 26, 2019 , and April 27, 2018

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Jul. 26, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use asset and lease liabilities in an amount of approximately $1.0 billion , an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others

Revenue

Revenue	3 Months Ended
	Jul. 26, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The table below illustrates net sales by segment and division for the three months ended July 26, 2019 and July 27, 2018 : Three months ended (1) (in millions) July 26, 2019 July 27, 2018 Cardiac Rhythm & Heart Failure $ 1,382 $ 1,426 Coronary & Structural Heart 941 917 Aortic, Peripheral, & Venous 467 468 Cardiac and Vascular Group 2,790 2,811 Surgical Innovations 1,417 1,397 Respiratory, Gastrointestinal, & Renal 683 655 Minimally Invasive Therapies Group 2,100 2,052 Brain Therapies 740 674 Spine 658 652 Specialty Therapies 322 309 Pain Therapies 292 314 Restorative Therapies Group 2,012 1,949 Diabetes Group 592 572 Total $ 7,493 $ 7,384 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for the three months ended July 27, 2018 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three months ended July 26, 2019 and July 27, 2018 : U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 1,361 $ 1,389 $ 930 $ 947 $ 499 $ 475 Minimally Invasive Therapies Group 913 857 791 828 396 367 Restorative Therapies Group 1,338 1,294 426 428 248 227 Diabetes Group 306 324 231 203 55 45 Total $ 3,918 $ 3,864 $ 2,377 $ 2,406 $ 1,198 $ 1,114 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. The amount of revenue recognized reflects sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases of revenue. At July 26, 2019 , $761 million of rebates were classified as other accrued expenses and $426 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. At April 26, 2019 , $764 million of rebates were classified as other accrued expenses and $432 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. The Company includes obligations for returns in other accrued expenses in the consolidated balance sheets and the right-of-return asset in o ther current assets in the consolidated balance sheets. The right-of-return asset and liability at July 26, 2019 and April 26, 2019 were no t material. For the three months ended July 26, 2019 and July 27, 2018 , adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were no t material. Deferred Revenue and Remaining Performance Obligations The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue at July 26, 2019 and April 26, 2019 was $295 million and $315 million , respectively. At July 26, 2019 and April 26, 2019 , $195 million and $211 million was included in other accrued expenses , respectively, and $100 million and $104 million was included in other liabilities , respectively. During the three months ended July 26, 2019 , the Company recognized $98 million of revenue that was included in deferred revenue as of April 26, 2019 . Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At July 26, 2019 , the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more was approximately $1.0 billion . The Company expects to recognize revenue on the majority of these remaining performance obligations over the next four years .

Acquisitions

Acquisitions	3 Months Ended
	Jul. 26, 2019
Business Combinations [Abstract]
Acquisitions	Acquisitions The Company had acquisitions during the three months ended July 26, 2019 and July 27, 2018 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three months ended July 26, 2019 and July 27, 2018 . The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. Fiscal Year 2020 The acquisition date fair value of net assets acquired in the first quarter of fiscal year 2020 was $206 million , consisting of $247 million of assets acquired and $41 million of liabilities assumed. Based upon preliminary valuations, assets acquired were primarily comprised of $91 million of technology-based intangible assets and $26 million of customer-related intangible assets with estimated useful lives of 8 years, $40 million of inventory, and $65 million of goodwill. The goodwill is not deductible for tax purposes. The Company recognized $ 58 million of contingent consideration liabilities in connection with business combinations during the first quarter of fiscal year 2020, which are comprised of revenue milestone-based payments. Additionally, in the first quarter of fiscal year 2020 , adjustments were made to the allocation of the purchase price for the Company's acquisitions of Mazor Robotics and EPiX Therapeutics, Inc., which were acquired during fiscal year 2019 . These adjustments primarily related to deferred taxes, which resulted in an increase to goodwill of $5 million . The measurement period for purchase accounting for these acquisitions will close during fiscal year 2020 . Fiscal Year 2019 The acquisition date fair value of net assets acquired in the first quarter of fiscal year 2019 was $150 million , consisting of $171 million of assets acquired and $21 million of liabilities assumed. Assets acquired were primarily comprised of $62 million of goodwill and $93 million of technology-based intangible assets with estimated useful lives ranging from 14 to 15 years. Contingent Consideration Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating (income) expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of contingent consideration at July 26, 2019 and April 26, 2019 was $269 million and $222 million , respectively. At July 26, 2019 , $64 million was recorded in other accrued expenses and $205 million was recorded in other liabilities in the consolidated balance sheets. At April 26, 2019 , $73 million was recorded in other accrued expenses and $149 million was recorded in other liabilities in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended (in millions) July 26, 2019 July 27, 2018 Beginning balance $ 222 $ 173 Purchase price contingent consideration 58 35 Payments (14 ) (6 ) Change in fair value 3 6 Ending balance $ 269 $ 208 The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected payment dates, discount rates, probabilities of payment, and projected revenues may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) July 26, 2019 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $135 Discounted cash flow Probability of payment 40% - 100% Projected fiscal year of payment 2020 - 2025 Discount rate 5.5% Product development and other milestone-based payments $134 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring

Restructuring	3 Months Ended
	Jul. 26, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which is expected to leverage the Company's global size and scale, as well as enhance the customer and employee experience, with a focus on three objectives: global operations, functional optimization, and commercial optimization. Primary activities of the restructuring program include integrating and enhancing global manufacturing and supply processes, systems and site presence, enhancing and leveraging global operating models across several enabling functions, and optimizing certain commercial processes, systems, and models. The Company estimates that, in connection with its Enterprise Excellence restructuring program, it will recognize pre-tax exit and disposal costs and other costs across all segments of approximately $1.6 billion to $1.8 billion , the majority of which are expected to be incurred by the end of fiscal year 2022. Approximately half of the estimated charges are related to employee termination benefits. The remaining restructuring charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 26, 2019 , the Company recognized $136 million in charges, partially offset by accrual adjustments of $12 million related to certain employees identified for termination finding other positions within Medtronic. Restructuring charges included $35 million recognized within cost of products sold and $42 million recognized within selling, general, and administrative expense in the consolidated statements of income. For the three months ended July 27, 2018 , the Company recognized $120 million in charges, partially offset by accrual adjustments related to certain employees identified for termination finding other positions within Medtronic. For the three months ended July 27, 2018 , restructuring charges included $15 million recognized within cost of products sold and $36 million recognized within selling, general, and administrative expense in the consolidated statements of income. The following table summarizes the activity related to the Enterprise Excellence restructuring program for the three months ended July 26, 2019 : (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 52 71 6 7 136 Cash payments (58 ) (62 ) — (7 ) (127 ) Settled non-cash — — (6 ) — (6 ) Accrual adjustments (5 ) — — (7 ) (12 ) July 26, 2019 $ 90 $ 18 $ — $ 5 $ 113 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	3 Months Ended
	Jul. 26, 2019
Investments [Abstract]
Financial Instruments	Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. For information regarding the valuation techniques and inputs used in the fair value measurements, refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 . The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 26, 2019 and April 26, 2019 : July 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 549 $ 8 $ — $ 557 $ 557 $ — Level 2: Corporate debt securities 3,123 30 (13 ) 3,140 3,140 — U.S. government and agency securities 788 — (2 ) 786 786 — Mortgage-backed securities 578 8 (14 ) 572 572 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 537 3 (3 ) 537 537 — Total Level 2 5,037 41 (32 ) 5,046 5,046 — Level 3: Auction rate securities 47 — (3 ) 44 — 44 Total available-for-sale debt securities $ 5,633 $ 49 $ (35 ) $ 5,647 $ 5,603 $ 44 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7 ) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21 ) 3,493 3,493 — U.S. government and agency securities 387 1 (7 ) 381 381 — Mortgage-backed securities 537 3 (20 ) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3 ) 527 527 — Total Level 2 4,964 19 (51 ) 4,932 4,932 — Level 3: Auction rate securities 47 — (3 ) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61 ) $ 5,499 $ 5,455 $ 44 The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 26, 2019 and April 26, 2019 : July 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government and agency securities $ 62 $ — $ 311 $ (2 ) Corporate debt securities 535 (8 ) 371 (5 ) Mortgage-backed securities 79 (1 ) 113 (13 ) Non-U.S. government and agency securities 3 — — — Other asset-backed securities 193 (2 ) 112 (1 ) Auction rate securities — — 44 (3 ) Total $ 872 $ (11 ) $ 951 $ (24 ) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government and agency securities $ 130 $ (1 ) $ 649 $ (13 ) Corporate debt securities 582 (5 ) 1,153 (16 ) Mortgage-backed securities 73 (1 ) 250 (19 ) Other asset-backed securities 290 (2 ) 85 (1 ) Auction rate securities — — 44 (3 ) Total $ 1,075 $ (9 ) $ 2,181 $ (52 ) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three months ended July 26, 2019 and July 27, 2018 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no purchases, sales, settlements, or gains or losses recognized in earnings or other comprehensive income for available-for-sale securities classified as Level 3 during the three months ended July 26, 2019 and July 27, 2018 . Activity related to the Company’s debt securities portfolio is as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Proceeds from sales $ 1,567 $ 1,112 Gross realized gains 4 6 Gross realized losses (8 ) (7 ) Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At July 26, 2019 and April 26, 2019 , the credit loss portion of other-than-temporary impairments on debt securities was no t significant. No available for sale securities were sold for significantly less than carrying value during the three months ended July 26, 2019 and July 27, 2018 . The July 26, 2019 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) July 26, 2019 Due in one year or less $ 1,157 Due after one year through five years 2,407 Due after five years through ten years 2,030 Due after ten years 53 Total $ 5,647 Equity Securities, Equity Method Investments, and Other Investments The Company holds investments in equity securities without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. The following table summarizes the Company's equity and other investments at July 26, 2019 and April 26, 2019 , which are classified as other assets in the consolidated balance sheets: (in millions) July 26, 2019 April 26, 2019 Investments without readily determinable fair values $ 308 $ 308 Equity method and other investments 64 64 Total equity and other investments $ 372 $ 372 The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended (in millions) July 26, 2019 July 27, 2018 Proceeds from sales $ 2 $ 908 Gross gains — 114 Gross losses — (16 ) Recognized impairment losses (1 ) — There were no realized or unrealized losses recognized during the three months ended July 26, 2019 . Net gains recognized during the three months ended July 27, 2018 were $98 million , comprised of $45 million of net realized gains on equity investments sold during the period and $53 million of net unrealized gains on equity and other investments held at July 27, 2018 . The Company did not recognize any significant impairment charges related to equity investments during the three months ended July 26, 2019 and July 27, 2018

Financing Arrangements

Financing Arrangements	3 Months Ended
	Jul. 26, 2019
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. No commercial paper was outstanding at both July 26, 2019 and April 26, 2019 . The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five -year unsecured revolving credit facility (Credit Facility) which provides back-up funding for the commercial paper program described above. At July 26, 2019 and April 26, 2019 , no amounts were outstanding under the Credit Facility. Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company was in compliance with at July 26, 2019 . Debt Obligations The Company's debt obligations consisted of the following: (in millions) Maturity by Fiscal Year July 26, 2019 April 26, 2019 Current debt obligations 2020 $ 1,458 $ 838 Long-term debt 0.000 percent two-year 2019 senior notes 2021 1,673 1,681 Floating rate two-year 2019 senior notes 2021 836 560 4.125 percent ten-year 2011 senior notes 2021 — 500 3.150 percent seven-year 2015 senior notes 2022 1,534 2,500 3.125 percent ten-year 2012 senior notes 2022 — 675 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 0.375 percent four-year 2019 senior notes 2023 1,673 1,681 2.750 percent ten-year 2013 senior notes 2023 531 530 0.000 percent four-year 2019 senior notes 2023 836 — 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 432 850 3.500 percent ten-year 2015 senior notes 2025 2,700 4,000 0.250 percent seven-year 2019 senior notes 2026 1,115 — 1.125 percent eight-year 2019 senior notes 2027 1,673 1,681 3.350 percent ten-year 2017 senior notes 2027 368 850 1.625 percent twelve-year 2019 senior notes 2031 1,115 1,121 1.000 percent thirteen-year 2019 senior notes 2032 1,115 — 4.375 percent twenty-year 2015 senior notes 2035 1,933 2,382 6.550 percent thirty-year 2007 CIFSA senior notes 2038 253 284 2.250 percent twenty-year 2019 senior notes 2039 1,115 1,121 6.500 percent thirty-year 2009 senior notes 2039 158 183 5.550 percent thirty-year 2010 senior notes 2040 224 306 1.500 percent twenty-year 2019 senior notes 2040 1,115 — 4.500 percent thirty-year 2012 senior notes 2042 105 129 4.000 percent thirty-year 2013 senior notes 2043 305 325 4.625 percent thirty-year 2014 senior notes 2044 127 177 4.625 percent thirty-year 2015 senior notes 2045 1,813 1,963 1.750 percent thirty-year 2019 senior notes 2050 1,115 — Bank borrowings 2021 - 2022 80 83 Debt (discount) premium, net 2020 - 2050 (16 ) 29 Finance lease obligations 2021 - 2033 32 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (116 ) (104 ) Long-term debt $ 24,804 $ 24,486 Senior Notes The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at July 26, 2019 . In June 2019, Medtronic Luxco issued six tranches of Euro-denominated Senior Notes with an aggregate principal of €5.0 billion , with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion , net of discounts and issuance costs. The issuance included €250 million of floating rate Senior Notes due in fiscal year 2021, €750 million of 0.000 percent Senior Notes due in fiscal year 2023, €1.0 billion of 0.250 percent Senior Notes due in fiscal year 2026, €1.0 billion of 1.000 percent Senior Notes due in fiscal year 2032, €1.0 billion of 1.500 percent Senior Notes due in fiscal year 2040, and €1.0 billion of 1.750 percent Senior Notes due in fiscal year 2050. The Company used the net proceeds of the offering to fund the cash tender offer and early redemption, described below. The Euro-denominated debt is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 8 for additional information regarding the net investment hedge. The Company completed the cash tender offer of $4.6 billion of Medtronic Inc., CIFSA, and Medtronic Luxco Senior Notes for $5.0 billion of total consideration in July 2019. The Company recognized a loss on debt extinguishment of $413 million during the three months ended July 26, 2019 , which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss on debt extinguishment also includes a $16 million charge for the estimated early redemption premium for $533 million of senior notes which were redeemed in August 2019. The loss on debt extinguishment was recognized in interest expense in the consolidated statements of income. Financial Instruments Not Measured at Fair Value At July 26, 2019 , the estimated fair value of the Company’s Senior Notes was $27.8 billion compared to a principal value of $25.9 billion . At April 26, 2019 , the estimated fair value was $26.2 billion compared to a principal value of $25.0 billion . The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	3 Months Ended
	Jul. 26, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro, Japanese Yen, and British Pound. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $10.8 billion and $11.1 billion at July 26, 2019 and April 26, 2019 , respectively. The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income. Freestanding Derivative Contracts Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's currency exchange rate contracts outstanding at July 26, 2019 and April 26, 2019 was $4.2 billion and $4.3 billion , respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows. The Company also uses total return swaps to hedge the liability of a non-qualified, deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at July 26, 2019 and April 26, 2019 was $201 million and $191 million , respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating activities in the consolidated statements of cash flows. The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) Classification July 26, 2019 July 27, 2018 Currency exchange rate contracts Other operating (income) expense, net $ (6 ) $ 130 Total return swaps Other operating (income) expense, net 5 11 Total $ (1 ) $ 141 Cash Flow Hedges Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at July 26, 2019 and April 26, 2019 was $6.7 billion and $6.8 billion , respectively, and will mature within the subsequent two-year period. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss . The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating (income) expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows. No components of the hedge contracts were excluded in the measurement of hedge effectiveness, and no forward contracts designated as cash flow hedges were derecognized or discontinued during the three months ended July 26, 2019 and July 27, 2018 . The amount of the gains (losses) recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Currency exchange rate contracts $ 27 $ 270 The amount of the gains (losses) recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended July 26, 2019 July 27, 2018 (in millions) Other operating (income) expense, net Other operating (income) expense, net Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow hedges are recorded $ (22 ) $ 151 Currency exchange rate contracts designated as cash flow hedges: Amount of gain (loss) reclassified from AOCI into income 57 (3 ) Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges are reported as a component of accumulated other comprehensive loss . Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the gains or losses are then reclassified into interest expense over the term of the related debt. For the three months ended July 26, 2019 and July 27, 2018 the reclassifications of net gains (losses) on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense were no t significant. At July 26, 2019 and April 26, 2019 the Company had $187 million and $194 million , respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $164 million of after-tax net unrealized gains at July 26, 2019 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Changes in the fair value of the derivative instrument are recognized in interest expense and are offset by changes in the fair value of the underlying debt instrument. The gains (losses) from terminated interest rate swap agreements are recognized in long-term debt , increasing (decreasing) the outstanding balances of the debt, and amortized as a reduction of (addition to) interest expense over the remaining life of the related debt. The cash flows related to the Company's interest rate derivative instruments designated as fair value hedges are reported as operating activities in the consolidated statements of cash flows. At July 26, 2019 the Company had no interest rate swaps outstanding designated as fair value hedges, as the Company terminated previously held swaps in connection with the tender and early redemption of the underlying senior notes. At April 26, 2019 , the Company had interest rate swaps in gross notional amounts of $1.2 billion , designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due fiscal year 2021 and the $675 million 3.125 percent 2012 Senior Notes due fiscal year 2022 . The gain recognized upon termination of the interest rate swaps was not significant for the three months ended July 26, 2019 . At April 26, 2019 , the market value of outstanding interest rate swap agreements was an unrealized gain of $9 million . The amounts were recorded in other assets , with the offsets recorded in long-term debt on the consolidated balance sheets. The Company did no t recognize any gains or losses during the three months ended July 26, 2019 and July 27, 2018 on firm commitments that no longer qualify as fair value hedges. The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet July 26, 2019 April 26, 2019 July 26, 2019 April 26, 2019 Long-term debt $ — $ (1,175 ) $ — $ 9 Net Investment Hedges The Company has designated Euro-denominated debt as a net investment hedge of certain of its European operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At July 26, 2019 , the Company had €12.0 billion , or $13.4 billion , of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations. These non-derivative instruments will mature in fiscal years 2021 through 2050. Additionally, during the first quarter of fiscal year 2020 , the Company entered into and settled forward currency exchange rate contracts to manage the exposure to exchange rate movements in anticipation of the issuance of Euro-denominated senior notes. Certain of these forward currency exchange rate contracts were designated as a net investment hedge of certain of the Company's European operations. These contracts matured in conjunction with the issuance of Euro-denominated debt in the first quarter of fiscal year 2020. For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss . The gains or losses are reclassified into earnings in the same period as a liquidation event or upon deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in other operating (income) expense, net . The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. At July 26, 2019 and April 26, 2019 the Company had $70 million and $169 million , respectively, in after-tax unrealized losses associated with net investment hedges recorded in accumulated other comprehensive loss . The Company does no t expect any of the after-tax unrealized losses at July 26, 2019 to be recognized in the consolidated statements of income over the next 12 months. The Company did no t recognize any gains or losses during the three months ended July 26, 2019 or July 27, 2018 on instruments that no longer qualify as net investment hedges. The amount and classifications of the gains recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended (in millions) Classification July 26, 2019 July 27, 2018 Net investment hedges Other operating (income) expense, net $ (7 ) $ — The amount of the gains recognized in AOCI related to instruments designated as net investment hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Net investment hedges $ 99 $ — Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at July 26, 2019 and April 26, 2019 . The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. July 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 212 Other accrued expenses $ 8 Currency exchange rate contracts Other assets 80 Other liabilities 4 Total derivatives designated as hedging instruments 292 12 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 16 Other accrued expenses 21 Total return swap Other current assets 5 Other accrued expenses — Cross currency interest rate contracts Other current assets 5 Other accrued expenses — Total derivatives not designated as hedging instruments 26 21 Total derivatives $ 318 $ 33 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. July 26, 2019 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 308 $ 10 $ 335 $ 30 Derivative liabilities 33 — 19 — The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows. The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 308 $ (19 ) $ (5 ) $ 284 Total return swaps 5 — — 5 Cross currency interest rate contracts 5 — — 5 318 (19 ) (5 ) 294 Derivative liabilities: Currency exchange rate contracts (33 ) 19 — (14 ) Total return swaps — — — — (33 ) 19 — (14 ) Total $ 285 $ — $ (5 ) $ 280 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9 ) $ (43 ) $ 283 Interest rate contracts 9 — (1 ) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9 ) (44 ) 312 Derivative liabilities: Currency exchange rate contracts (19 ) 9 — (10 ) (19 ) 9 — (10 ) Total $ 346 $ — $ (44 ) $ 302

Inventories

Inventories	3 Months Ended
	Jul. 26, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory balances, net of reserves, were as follows: (in millions) July 26, 2019 April 26, 2019 Finished goods $ 2,628 $ 2,476 Work in-process 569 572 Raw materials 735 705 Total $ 3,932 $ 3,753

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Jul. 26, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — — 65 — 65 Purchase accounting adjustments 6 1 (2 ) — 5 Currency translation and other 6 56 (9 ) — 53 July 26, 2019 $ 6,866 $ 20,438 $ 10,875 $ 1,903 $ 40,082 The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did no t recognize any goodwill impairment during the three months ended July 26, 2019 or July 27, 2018 . Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: July 26, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,968 $ (4,337 ) $ 16,944 $ (4,095 ) Purchased technology and patents 10,792 (4,059 ) 11,405 (4,570 ) Trademarks and tradenames 464 (220 ) 570 (324 ) Other 74 (51 ) 85 (59 ) Total $ 28,298 $ (8,667 ) $ 29,004 $ (9,048 ) Indefinite-lived: IPR&D $ 603 $ — $ 604 $ — The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did no t recognize any definite-lived intangible asset charges during the three months ended July 26, 2019 . The Company recognized $61 million of definite-lived intangible asset charges during the three months ended July 27, 2018 , in connection with the exit of a business within the Cardiac and Vascular Group segment, which were recognized in other operating (income) expense, net in the consolidated statements of income. The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The Company did no t recognize any indefinite-lived intangibles impairments during the three months ended July 26, 2019 or July 27, 2018 . Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation a certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three months ended July 26, 2019 was $440 million as compared to $ 446 million for the three months ended July 27, 2018 . Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at July 26, 2019 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 1,315 2021 1,738 2022 1,698 2023 1,630 2024 1,593 2025 1,560

Income Taxes

Income Taxes	3 Months Ended
	Jul. 26, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s effective tax rate for the three months ended July 26, 2019 was 10.2 percent , as compared to 8.7 percent for the three months ended July 27, 2018 . The increase in the effective tax rate for the three months ended July 26, 2019 , as compared to the corresponding period in the prior fiscal year, was due to the impact of the lapse of federal statutes of limitations in the prior year, and year-over-year changes in operational results by jurisdiction. Certain Tax Adjustments During the three months ended July 26, 2019 , the net benefit from certain tax adjustments of $30 million , recognized in income tax provision in the consolidated statements of income, included the following: • A net benefit of $30 million related to U.S. Treasury’s issuance of certain Final Regulations associated with U.S. Tax Reform. The primary impact of these regulations resulted in the Company re-establishing its permanently reinvested assertion on certain foreign earnings and reversing the previously accrued tax liability. This benefit was partially offset by additional tax associated with a previously executed internal reorganization of certain foreign subsidiaries. During the three months ended July 27, 2018 , the net benefit from certain tax adjustments of $29 million , recognized in income tax provision in the consolidated statements of income, included the following: • A benefit of $50 million associated with the transition tax liability recorded in connection with U.S. Tax Reform. • A charge of $21 million related to the recognition of a prepaid tax expense resulting from the reduction in the U.S. statutory tax rate due to U.S. Tax Reform and the sale of U.S. manufactured inventory held as of April 27, 2018. The Company records tax liabilities in the consolidated financial statements for amounts that it expects to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts that are considered permanently reinvested. The Company had removed its permanently reinvested assertion on the undistributed earnings of certain foreign subsidiaries with a U.S. parent which were subject to the transition tax and all earnings of these subsidiaries through April 27, 2018. As a result of the issuance of Final Regulations during the quarter, the Company reestablished its permanently reinvested assertion for certain pre-April 27, 2018 earnings that were not subjected to the transition tax. At July 26, 2019 and April 26, 2019 , the Company's gross unrecognized tax benefits were $1.9 billion and $1.8 billion , respectively. In addition, the Company had accrued gross interest and penalties of $186 million at July 26, 2019 . If all the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. At both July 26, 2019 and April 26, 2019 , the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets. Refer to Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Jul. 26, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended (in millions, except per share data) July 26, 2019 July 27, 2018 Numerator: Net income attributable to ordinary shareholders $ 864 $ 1,075 Denominator: Basic – weighted average shares outstanding 1,340.8 1,352.7 Effect of dilutive securities: Employee stock options 6.9 8.4 Employee restricted stock units 3.5 3.6 Other 0.7 0.7 Diluted – weighted average shares outstanding 1,351.9 1,365.4 Basic earnings per share $ 0.64 $ 0.79 Diluted earnings per share $ 0.64 $ 0.79 The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 3 million and 6 million ordinary shares for the three months ended July 26, 2019 and July 27, 2018

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Jul. 26, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three months ended July 26, 2019 and July 27, 2018 : Three months ended (in millions) July 26, 2019 July 27, 2018 Stock options $ 9 $ 18 Restricted stock 42 36 Employee stock purchase plan 10 10 Total stock-based compensation expense $ 61 $ 64 Cost of products sold $ 6 $ 6 Research and development expense 7 8 Selling, general, and administrative expense 48 50 Total stock-based compensation expense 61 64 Income tax benefits (10 ) (11 ) Total stock-based compensation expense, net of tax $ 51 $ 53

Retirement Benefit Plans

Retirement Benefit Plans	3 Months Ended
	Jul. 26, 2019
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 26, 2019 and July 27, 2018 : U.S. Non-U.S. Three months ended Three months ended (in millions) July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56 ) (54 ) (15 ) (14 ) Amortization of net actuarial loss 14 19 3 3 Net periodic benefit cost $ 16 $ 25 $ 10 $ 11 Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net

Leases

Leases	3 Months Ended
	Jul. 26, 2019
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed. The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for the three months ended July 26, 2019 were not material. The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases are not material to the consolidated financial statements at or for the three months ended July 26, 2019 . Finance lease right-of-use assets are included in property, plant, and equipment, net , and finance lease liabilities are included in current debt obligations and long-term debt on the consolidated balance sheets. Additionally, from time to time, the Company subleases portions of its real-estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the three months ended July 26, 2019 . The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use asset and lease liability at July 26, 2019 : (in millions) Balance Sheet Classification July 26, 2019 Right-of-use assets Other assets $ 948 Current liability Other accrued expenses 183 Non-current liability Other liabilities 795 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at July 26, 2019 : July 26, 2019 Weighted-average remaining lease term 7.5 years Weighted-average discount rate 3.0% The following table summarizes the components of our total operating lease cost for the three months ended July 26, 2019 : Three months ended (in millions) July 26, 2019 Operating lease cost $ 55 Short-term lease cost 11 Total operating lease cost $ 66 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for new operating lease liabilities for the three months ended July 26, 2019 : Three months ended (in millions) July 26, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 57 Right-of-use assets obtained in exchange for new operating lease liabilities 49 The following table summarizes the maturities of the Company's operating leases at July 26, 2019 : (in millions) Fiscal Year Operating Leases Remaining 2020 $ 152 2021 184 2022 153 2023 132 2024 111 Thereafter 432 Total expected lease payments 1,164 Less: Imputed interest (186 ) Total lease liability $ 978 The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within net sales in the consolidated statements of income and the Company's net investments in sales-type leases are included in other current assets and other assets in the consolidated balance sheets. Lessor income and the related assets and lease maturities are not material to the consolidated financial statements at or for the three months ended July 26, 2019 . As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019 , minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Fiscal Year Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Jul. 26, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45 ) $ (1,383 ) $ (169 ) $ (1,308 ) $ 194 $ (2,711 ) Other comprehensive income before reclassifications 51 66 99 — 26 242 Reclassifications 5 — — 13 (33 ) (15 ) Other comprehensive income (loss) 56 66 99 13 (7 ) 227 July 26, 2019 $ 11 $ (1,317 ) $ (70 ) $ (1,295 ) $ 187 $ (2,484 ) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194 ) $ (11 ) $ (257 ) $ (1,117 ) $ (207 ) $ (1,786 ) Other comprehensive (loss) income before reclassifications — (824 ) — — 209 (615 ) Reclassifications — — — 27 4 31 Other comprehensive (loss) income — (824 ) — 27 213 (584 ) Cumulative effect of change in accounting principle (1) 47 — — — — 47 July 27, 2018 $ (147 ) $ (835 ) $ (257 ) $ (1,090 ) $ 6 $ (2,323 ) (1) The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $ 47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018. The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the three months ended July 26, 2019 was a benefit of $1 million . There was no income tax on gains and losses on investment securities for the three months ended July 27, 2018 . During the three months ended July 26, 2019 , realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $1 million . There was no income tax on realized gains and losses on investment securities reclassified from AOCI for the three months ended July 27, 2018 . When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 6 to the consolidated financial statements for additional information. For the three months ended July 26, 2019 , there was no income tax on cumulative translation adjustments. For the three months ended July 27, 2018 , the income tax benefit on cumulative translation adjustments was $5 million. During the three months ended July 26, 2019 and July 27, 2018 , there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information. The net change in retirement obligations in other comprehensive income includes net amortization of actuarial losses included in net periodic benefit cost. During the three months ended July 26, 2019 and July 27, 2018 , there were no income tax impacts on the net change in retirement obligations in other comprehensive income before reclassifications. During the three months ended July 26, 2019 and July 27, 2018 , the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $3 million and $5 million , respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 14 to the consolidated financial statements for additional information. The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the three months ended July 26, 2019 and July 27, 2018 was an expense of $1 million and $60 million , respectively. During the three months ended July 26, 2019 and July 27, 2018 , gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of $11 million and $1 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating (income) expense, net, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jul. 26, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At July 26, 2019 and April 26, 2019 , accrued litigation was approximately $0.5 billion . The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Pelvic Mesh Litigation The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of August 7, 2019, the Company had reached agreements to settle approximately 15,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Sasso The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million . The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable under U.S. GAAP. Shareholder Related Matters Covidien Acquisition On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in February of 2020. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Government Matters Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. U.S. Tax Court trial is scheduled to occur in April of 2020. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level. Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Refer to Note 11 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is 42 percent , with Johnson Controls and TE Connectivity share being 27 percent , and 31 percent , respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation. Refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 for additional information. As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Jul. 26, 2019
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments. The Company’s management evaluates performance of the segments and allocates resources based on segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosure for the prior period to align with the current presentation. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 . Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) (in millions) July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 2,790 $ 2,811 Minimally Invasive Therapies Group 2,100 2,052 Restorative Therapies Group 2,012 1,949 Diabetes Group 592 572 Total $ 7,493 $ 7,384 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Segment Operating Profit Three months ended (in millions) July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 1,055 $ 1,049 Minimally Invasive Therapies Group 771 776 Restorative Therapies Group 793 766 Diabetes Group 149 172 Segment operating profit 2,768 2,763 Interest expense (609 ) (242 ) Other non-operating income, net 101 186 Amortization of intangible assets (440 ) (446 ) Corporate (307 ) (303 ) Centralized distribution costs (345 ) (446 ) Restructuring and associated costs (124 ) (113 ) Acquisition-related items (19 ) (36 ) Certain litigation charges (47 ) (103 ) Exit of businesses — (80 ) Debt tender premium and other charges 7 — Medical device regulations (8 ) — Income before income taxes $ 977 $ 1,180 Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three months ended July 26, 2019 and July 27, 2018 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended (in millions) July 26, 2019 July 27, 2018 Ireland $ 20 $ 22 United States 3,918 3,864 Rest of world 3,555 3,498 Total other countries, excluding Ireland 7,473 7,362 Total $ 7,493 $ 7,384

Guarantor Financial Information

Guarantor Financial Information	3 Months Ended
	Jul. 26, 2019
Condensed Financial Information Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Additionally, Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of Medtronic Luxco Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic Luxco • Subsidiary Guarantor - Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors) The following presents the Company’s consolidating statements of comprehensive income for the three months ended July 26, 2019 and July 27, 2018 , condensed consolidating balance sheets at July 26, 2019 and April 26, 2019 , and condensed consolidating statements of cash flows for the three months ended July 26, 2019 and July 27, 2018 . The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. During the three months ended July 26, 2019 Consolidating Statement of Comprehensive Income Three Months Ended July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 426 $ — $ 7,493 $ (426 ) $ 7,493 Costs and expenses: Cost of products sold — 326 — 2,351 (311 ) 2,366 Research and development expense — 168 — 419 — 587 Selling, general, and administrative expense 2 378 — 2,163 — 2,543 Amortization of intangible assets — 3 — 437 — 440 Restructuring charges, net — 3 — 44 — 47 Certain litigation charges — 5 — 42 — 47 Other operating expense (income), net 13 (439 ) (7 ) 500 (89 ) (22 ) Operating profit (loss) (15 ) (18 ) 7 1,537 (26 ) 1,485 Other non-operating (income) expense, net — (61 ) (245 ) (404 ) 609 (101 ) Interest expense 145 712 164 197 (609 ) 609 Equity in net (income) loss of subsidiaries (1,022 ) (610 ) (934 ) — 2,566 — Income (loss) before income taxes 862 (59 ) 1,022 1,744 (2,592 ) 977 Income tax (benefit) provision (2 ) (129 ) — 231 — 100 Net income (loss) 864 70 1,022 1,513 (2,592 ) 877 Net income attributable to noncontrolling interests — — — (13 ) — (13 ) Net income (loss) attributable to Medtronic 864 70 1,022 1,500 (2,592 ) 864 Other comprehensive income (loss), net of tax 227 46 227 108 (381 ) 227 Comprehensive income attributable to noncontrolling interests — — — (13 ) — (13 ) Total comprehensive income (loss) $ 1,091 $ 116 $ 1,249 $ 1,608 $ (2,973 ) $ 1,091 Consolidating Statement of Comprehensive Income Three Months Ended July 27, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 362 $ — $ 7,384 $ (362 ) $ 7,384 Costs and expenses: Cost of products sold — 273 — 2,168 (237 ) 2,204 Research and development expense — 168 — 417 — 585 Selling, general, and administrative expense 3 366 — 2,228 — 2,597 Amortization of intangible assets — 2 — 444 — 446 Restructuring charges, net — 10 — 52 — 62 Certain litigation charges — 78 — 25 — 103 Other operating expense (income), net — (259 ) — 511 (101 ) 151 Operating profit (loss) (3 ) (276 ) — 1,539 (24 ) 1,236 Other non-operating (income) expense, net — (160 ) (164 ) (504 ) 642 (186 ) Interest expense 99 465 103 217 (642 ) 242 Equity in net (income) loss of subsidiaries (1,175 ) (814 ) (1,114 ) — 3,103 — Income (loss) before income taxes 1,073 233 1,175 1,826 (3,127 ) 1,180 Income tax (benefit) provision (2 ) (104 ) — 209 — 103 Net income (loss) 1,075 337 1,175 1,617 (3,127 ) 1,077 Net income attributable to noncontrolling interests — — — (2 ) — (2 ) Net income (loss) attributable to Medtronic 1,075 337 1,175 1,615 (3,127 ) 1,075 Other comprehensive (loss) income, net of tax (584 ) (507 ) (584 ) (604 ) 1,695 (584 ) Comprehensive loss attributable to noncontrolling interests — — — (2 ) — (2 ) Total comprehensive income (loss) $ 491 $ (170 ) $ 591 $ 1,011 $ (1,432 ) $ 491 Condensed Consolidating Balance Sheet July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 15 $ 93 $ 4,972 $ — $ 5,080 Investments — — — 5,603 — 5,603 Accounts receivable, net — — — 5,894 — 5,894 Inventories, net — 184 — 3,998 (250 ) 3,932 Intercompany receivable 80 9,837 5 30,756 (40,678 ) — Other current assets 16 212 3 1,965 — 2,196 Total current assets 96 10,248 101 53,188 (40,928 ) 22,705 Property, plant, and equipment, net — 1,508 — 3,203 — 4,711 Goodwill — 2,009 — 38,073 — 40,082 Other intangible assets, net — 96 — 20,138 — 20,234 Tax assets — 494 — 1,051 — 1,545 Investment in subsidiaries 65,549 72,421 66,048 — (204,018 ) — Intercompany loans receivable 3,000 21 29,017 25,238 (57,276 ) — Other assets — 308 — 1,683 — 1,991 Total assets $ 68,645 $ 87,105 $ 95,166 $ 142,574 $ (302,222 ) $ 91,268 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,033 $ — $ 425 $ — $ 1,458 Accounts payable — 492 — 1,414 — 1,906 Intercompany payable — 21,093 9,662 9,923 (40,678 ) — Accrued compensation 12 532 — 963 — 1,507 Accrued income taxes — — — 500 — 500 Other accrued expenses 20 467 39 2,621 — 3,147 Total current liabilities 32 23,617 9,701 15,846 (40,678 ) 8,518 Long-term debt — 9,780 13,601 1,423 — 24,804 Accrued compensation and retirement benefits — 1,070 — 570 — 1,640 Accrued income taxes 10 709 — 2,154 — 2,873 Intercompany loans payable 18,240 9,011 13,320 16,705 (57,276 ) — Deferred tax liabilities — — — 1,346 — 1,346 Other liabilities — 223 — 1,367 — 1,590 Total liabilities 18,282 44,410 36,622 39,411 (97,954 ) 40,771 Shareholders’ equity 50,363 42,695 58,544 103,029 (204,268 ) 50,363 Noncontrolling interests — — — 134 — 134 Total equity 50,363 42,695 58,544 103,163 (204,268 ) 50,497 Total liabilities and equity $ 68,645 $ 87,105 $ 95,166 $ 142,574 $ (302,222 ) $ 91,268 Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227 ) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623 ) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850 ) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,129 65,012 — (200,493 ) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277 ) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620 ) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623 ) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623 ) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277 ) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900 ) 39,482 Shareholders' equity 50,091 42,204 57,324 101,192 (200,720 ) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,204 57,324 101,313 (200,720 ) 50,212 Total liabilities and equity $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620 ) $ 89,694 Condensed Consolidating Statement of Cash Flows Three Months Ended July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ (115 ) $ (803 ) $ 150 $ 2,278 $ — $ 1,510 Investing Activities: Acquisitions, net of cash acquired — — — (145 ) — (145 ) Additions to property, plant, and equipment — (74 ) — (227 ) — (301 ) Purchases of investments — — — (1,669 ) — (1,669 ) Sales and maturities of investments — — — 1,569 — 1,569 Other investing activities — — (5 ) — — (5 ) Net cash provided by (used in) investing activities — (74 ) (5 ) (472 ) — (551 ) Financing Activities: Change in current debt obligations, net — — — 88 — 88 Issuance of long-term debt — — 5,567 — — 5,567 Payments on long-term debt — (4,463 ) (515 ) (57 ) — (5,035 ) Dividends to shareholders (724 ) — — — — (724 ) Issuance of ordinary shares 210 — — — — 210 Repurchase of ordinary shares (333 ) — — — — (333 ) Net intercompany loan borrowings (repayments) 962 5,337 (5,058 ) (1,241 ) — — Other financing activities — — (47 ) — — (47 ) Net cash provided by (used in) financing activities 115 874 (53 ) (1,210 ) — (274 ) Effect of exchange rate changes on cash and cash equivalents — — — 2 — 2 Net change in cash and cash equivalents — (3 ) 92 598 — 687 Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ 15 $ 93 $ 4,972 $ — $ 5,080 Condensed Consolidating Statement of Cash Flows Three Months Ended July 27, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (6 ) $ (387 ) $ 72 $ 2,023 $ — $ 1,702 Investing Activities: Acquisitions, net of cash acquired — — — (104 ) — (104 ) Additions to property, plant, and equipment — (49 ) — (242 ) — (291 ) Purchases of investments — — — (982 ) — (982 ) Sales and maturities of investments — 76 — 1,944 — 2,020 Capital contribution paid — (32 ) — — 32 — Net cash provided by (used in) investing activities — (5 ) — 616 32 643 Financing Activities: Change in current debt obligations, net — — (472 ) (33 ) — (505 ) Payments on long-term debt — — — (12 ) — (12 ) Dividends to shareholders (677 ) — — — — (677 ) Issuance of ordinary shares 450 — — — — 450 Repurchase of ordinary shares (824 ) — — — — (824 ) Net intercompany loan borrowings (repayments) 1,057 396 789 (2,242 ) — — Capital contribution received — — — 32 (32 ) — Other financing activities — — — (5 ) — (5 ) Net cash provided by (used in) financing activities 6 396 317 (2,260 ) (32 ) (1,573 ) Effect of exchange rate changes on cash and cash equivalents — — — (61 ) — (61 ) Net change in cash and cash equivalents — 4 389 318 — 711 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 24 $ 390 $ 3,966 $ — $ 4,380 Consolidating Statement of Comprehensive Income Three Months Ended July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,493 $ — $ 7,493 Costs and expenses: Cost of products sold — — — 2,366 — 2,366 Research and development expense — — — 587 — 587 Selling, general, and administrative expense 2 — — 2,541 — 2,543 Amortization of intangible assets — — — 440 — 440 Restructuring charges, net — — — 47 — 47 Certain litigation charges — — — 47 — 47 Other operating expense (income), net 13 — (7 ) (28 ) — (22 ) Operating profit (loss) (15 ) — 7 1,493 — 1,485 Other non-operating (income) expense, net — (63 ) (253 ) (397 ) 612 (101 ) Interest expense 145 221 165 690 (612 ) 609 Equity in net (income) loss of subsidiaries (1,022 ) (968 ) (927 ) — 2,917 — Income (loss) before income taxes 862 810 1,022 1,200 (2,917 ) 977 Income tax (benefit) provision (2 ) — — 102 — 100 Net income (loss) 864 810 1,022 1,098 (2,917 ) 877 Net income attributable to noncontrolling interests — — — (13 ) — (13 ) Net income (loss) attributable to Medtronic 864 810 1,022 1,085 (2,917 ) 864 Other comprehensive income (loss), net of tax 227 84 227 128 (439 ) 227 Comprehensive income attributable to noncontrolling interests — — — (13 ) — (13 ) Total comprehensive income (loss) $ 1,091 $ 894 $ 1,249 $ 1,213 $ (3,356 ) $ 1,091 Consolidating Statement of Comprehensive Income Three Months Ended July 27, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,384 $ — $ 7,384 Costs and expenses: Cost of products sold — — — 2,204 — 2,204 Research and development expense — — — 585 — 585 Selling, general, and administrative expense 3 — 1 2,593 — 2,597 Amortization of intangible assets — — — 446 — 446 Restructuring charges, net — — — 62 — 62 Certain litigation charges — — — 103 — 103 Other operating expense, net — — — 146 5 151 Operating profit (loss) (3 ) — (1 ) 1,245 (5 ) 1,236 Other non-operating (income) expense, net — (11 ) (170 ) (273 ) 268 (186 ) Interest expense 99 21 103 287 (268 ) 242 Equity in net (income) loss of subsidiaries (1,175 ) (972 ) (1,109 ) — 3,256 — Income (loss) before income taxes 1,073 962 1,175 1,231 (3,261 ) 1,180 Income tax (benefit) provision (2 ) — — 105 — 103 Net income (loss) 1,075 962 1,175 1,126 (3,261 ) 1,077 Net income attributable to noncontrolling interests — — — (2 ) — (2 ) Net income (loss) attributable to Medtronic 1,075 962 1,175 1,124 (3,261 ) 1,075 Other comprehensive (loss) income, net of tax (584 ) (40 ) (584 ) (584 ) 1,208 (584 ) Comprehensive loss attributable to — — — (2 ) — (2 ) Total comprehensive income (loss) $ 491 $ 922 $ 591 $ 540 $ (2,053 ) $ 491 Condensed Consolidating Balance Sheet July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 93 $ 4,987 $ — $ 5,080 Investments — — — 5,603 — 5,603 Accounts receivable, net — — — 5,894 — 5,894 Inventories, net — — — 3,932 — 3,932 Intercompany receivable 80 — 1,381 9,690 (11,151 ) — Other current assets 16 — 3 2,177 — 2,196 Total current assets 96 — 1,477 32,283 (11,151 ) 22,705 Property, plant, and equipment, net — — — 4,711 — 4,711 Goodwill — — — 40,082 — 40,082 Other intangible assets, net — — — 20,234 — 20,234 Tax assets — — — 1,545 — 1,545 Investment in subsidiaries 65,549 57,719 64,661 — (187,929 ) — Intercompany loans receivable 3,000 3,989 29,017 40,447 (76,453 ) — Other assets — — — 1,991 — 1,991 Total assets $ 68,645 $ 61,708 $ 95,155 $ 141,293 $ (275,533 ) $ 91,268 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 1,458 $ — $ 1,458 Accounts payable — — — 1,906 — 1,906 Intercompany payable — 1,316 9,662 173 (11,151 ) — Accrued compensation 12 — — 1,495 — 1,507 Accrued income taxes — — — 500 — 500 Other accrued expenses 20 8 44 3,075 — 3,147 Total current liabilities 32 1,324 9,706 8,607 (11,151 ) 8,518 Long-term debt — 1,311 13,601 9,892 — 24,804 Accrued compensation and retirement benefits — — — 1,640 — 1,640 Accrued income taxes 10 — — 2,863 — 2,873 Intercompany loans payable 18,240 27,127 13,320 17,766 (76,453 ) — Deferred tax liabilities — — — 1,346 — 1,346 Other liabilities — — 1 1,589 — 1,590 Total liabilities 18,282 29,762 36,628 43,703 (87,604 ) 40,771 Shareholders’ equity 50,363 31,946 58,527 97,456 (187,929 ) 50,363 Noncontrolling interests — — — 134 — 134 Total equity 50,363 31,946 58,527 97,590 (187,929 ) 50,497 Total liabilities and equity $ 68,645 $ 61,708 $ 95,155 $ 141,293 $ (275,533 ) $ 91,268 Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626 ) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626 ) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,557 63,651 — (167,560 ) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979 ) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165 ) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626 ) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626 ) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979 ) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605 ) 39,482 Shareholders' equity 50,091 31,683 57,324 78,553 (167,560 ) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,683 57,324 78,674 (167,560 ) 50,212 Total liabilities and equity $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165 ) $ 89,694 Condensed Consolidating Statement of Cash Flows Three Months Ended July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (115 ) $ (161 ) $ 157 $ 1,629 $ — $ 1,510 Investing Activities: Acquisitions, net of cash acquired — — — (145 ) — (145 ) Additions to property, plant, and equipment — — — (301 ) — (301 ) Purchases of investments — — — (1,669 ) — (1,669 ) Sales and maturities of investments — — — 1,569 — 1,569 Capital contribution paid — (6 ) — — 6 — Other investing activities — — (5 ) — — (5 ) Net cash provided by (used in) investing activities — (6 ) (5 ) (546 ) 6 (551 ) Financing Activities: Change in current debt obligations, net — — — 88 — 88 Issuance of long-term debt — — 5,567 — — 5,567 Payments on long-term debt — (44 ) (515 ) (4,476 ) — (5,035 ) Dividends to shareholders (724 ) — — — — (724 ) Issuance of ordinary shares 210 — — — — 210 Repurchase of ordinary shares (333 ) — — — — (333 ) Net intercompany loan borrowings (repayments) 962 211 (5,065 ) 3,892 — — Capital contribution received — — — 6 (6 ) — Other financing activities — — (47 ) — — (47 ) Net cash provided by (used in) financing activities 115 167 (60 ) (490 ) (6 ) (274 ) Effect of exchange rate changes on cash and cash equivalents — — — 2 — 2 Net change in cash and cash equivalents — — 92 595 — 687 Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 93 $ 4,987 $ — $ 5,080 Condensed Consolidating Statement of Cash Flows Three Months Ended July 27, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (6 ) $ (24 ) $ 77 $ 1,655 $ — $ 1,702 Investing Activities: Acquisitions, net of cash acquired — — — (104 ) — (104 ) Additions to property, plant, and equipment — — — (291 ) — (291 ) Purchases of investments — — — (982 ) — (982 ) Sales and maturities of investments — — — 2,020 — 2,020 Capital contributions paid — (185 ) — — 185 — Net cash provided by (used in) investing activities — (185 ) — 643 185 643 Financing Activities: Change in current debt obligations, net — — (473 ) (32 ) — (505 ) Payments on long-term debt — — — (12 ) — (12 ) Dividends to shareholders (677 ) — — — — (677 ) Issuance of ordinary shares 450 — — — — 450 Repurchase of ordinary shares (824 ) — — — — (824 ) Net intercompany loan borrowings (repayments) 1,057 209 785 (2,051 ) — — Capital contributions received — — — 185 (185 ) — Other financing activities — — — (5 ) — (5 ) Net cash provided by (used in) financing activities 6 209 312 (1,915 ) (185 ) (1,573 ) Effect of exchange rate changes on cash and cash equivalents — — — (61 ) — (61 ) Net change in cash and cash equivalents — — 389 322 — 711 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 390 $ 3,990 $ — $ 4,380

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Jul. 26, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2020 , 2019 , and 2018 will end or ended on April 24, 2020 , April 26, 2019 , and April 27, 2018 , respectively.
New Accounting Pronouncements	Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use asset and lease liabilities in an amount of approximately $1.0 billion , an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Jul. 26, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The table below illustrates net sales by market geography for each segment for the three months ended July 26, 2019 and July 27, 2018 : U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 1,361 $ 1,389 $ 930 $ 947 $ 499 $ 475 Minimally Invasive Therapies Group 913 857 791 828 396 367 Restorative Therapies Group 1,338 1,294 426 428 248 227 Diabetes Group 306 324 231 203 55 45 Total $ 3,918 $ 3,864 $ 2,377 $ 2,406 $ 1,198 $ 1,114 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. The table below illustrates net sales by segment and division for the three months ended July 26, 2019 and July 27, 2018 : Three months ended (1) (in millions) July 26, 2019 July 27, 2018 Cardiac Rhythm & Heart Failure $ 1,382 $ 1,426 Coronary & Structural Heart 941 917 Aortic, Peripheral, & Venous 467 468 Cardiac and Vascular Group 2,790 2,811 Surgical Innovations 1,417 1,397 Respiratory, Gastrointestinal, & Renal 683 655 Minimally Invasive Therapies Group 2,100 2,052 Brain Therapies 740 674 Spine 658 652 Specialty Therapies 322 309 Pain Therapies 292 314 Restorative Therapies Group 2,012 1,949 Diabetes Group 592 572 Total $ 7,493 $ 7,384 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Jul. 26, 2019
Business Combinations [Abstract]
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended (in millions) July 26, 2019 July 27, 2018 Beginning balance $ 222 $ 173 Purchase price contingent consideration 58 35 Payments (14 ) (6 ) Change in fair value 3 6 Ending balance $ 269 $ 208
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) July 26, 2019 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $135 Discounted cash flow Probability of payment 40% - 100% Projected fiscal year of payment 2020 - 2025 Discount rate 5.5% Product development and other milestone-based payments $134 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Jul. 26, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table summarizes the activity related to the Enterprise Excellence restructuring program for the three months ended July 26, 2019 : (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 52 71 6 7 136 Cash payments (58 ) (62 ) — (7 ) (127 ) Settled non-cash — — (6 ) — (6 ) Accrual adjustments (5 ) — — (7 ) (12 ) July 26, 2019 $ 90 $ 18 $ — $ 5 $ 113 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Jul. 26, 2019
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification, Debt Securities	The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at July 26, 2019 and April 26, 2019 : July 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 549 $ 8 $ — $ 557 $ 557 $ — Level 2: Corporate debt securities 3,123 30 (13 ) 3,140 3,140 — U.S. government and agency securities 788 — (2 ) 786 786 — Mortgage-backed securities 578 8 (14 ) 572 572 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 537 3 (3 ) 537 537 — Total Level 2 5,037 41 (32 ) 5,046 5,046 — Level 3: Auction rate securities 47 — (3 ) 44 — 44 Total available-for-sale debt securities $ 5,633 $ 49 $ (35 ) $ 5,647 $ 5,603 $ 44 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7 ) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21 ) 3,493 3,493 — U.S. government and agency securities 387 1 (7 ) 381 381 — Mortgage-backed securities 537 3 (20 ) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3 ) 527 527 — Total Level 2 4,964 19 (51 ) 4,932 4,932 — Level 3: Auction rate securities 47 — (3 ) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61 ) $ 5,499 $ 5,455 $ 44
Available-For-Sale Debt Securities in Continuous Unrealized Loss Position	The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 26, 2019 and April 26, 2019 : July 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government and agency securities $ 62 $ — $ 311 $ (2 ) Corporate debt securities 535 (8 ) 371 (5 ) Mortgage-backed securities 79 (1 ) 113 (13 ) Non-U.S. government and agency securities 3 — — — Other asset-backed securities 193 (2 ) 112 (1 ) Auction rate securities — — 44 (3 ) Total $ 872 $ (11 ) $ 951 $ (24 ) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government and agency securities $ 130 $ (1 ) $ 649 $ (13 ) Corporate debt securities 582 (5 ) 1,153 (16 ) Mortgage-backed securities 73 (1 ) 250 (19 ) Other asset-backed securities 290 (2 ) 85 (1 ) Auction rate securities — — 44 (3 ) Total $ 1,075 $ (9 ) $ 2,181 $ (52 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) July 26, 2019 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $135 Discounted cash flow Probability of payment 40% - 100% Projected fiscal year of payment 2020 - 2025 Discount rate 5.5% Product development and other milestone-based payments $134 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027
Activity Related to the Company's Debt Securities Portfolio	Activity related to the Company’s debt securities portfolio is as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Proceeds from sales $ 1,567 $ 1,112 Gross realized gains 4 6 Gross realized losses (8 ) (7 )
Available-for-sale Debt Securities Contractual Maturities	The July 26, 2019 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) July 26, 2019 Due in one year or less $ 1,157 Due after one year through five years 2,407 Due after five years through ten years 2,030 Due after ten years 53 Total $ 5,647
Summary of Equity and Other Investments	The following table summarizes the Company's equity and other investments at July 26, 2019 and April 26, 2019 , which are classified as other assets in the consolidated balance sheets: (in millions) July 26, 2019 April 26, 2019 Investments without readily determinable fair values $ 308 $ 308 Equity method and other investments 64 64 Total equity and other investments $ 372 $ 372
Activity Related to the Company's Equity and Other Investments Portfolio	The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended (in millions) July 26, 2019 July 27, 2018 Proceeds from sales $ 2 $ 908 Gross gains — 114 Gross losses — (16 ) Recognized impairment losses (1 ) —

Financing Arrangements (Tables)

Financing Arrangements (Tables)	3 Months Ended
	Jul. 26, 2019
Debt Disclosure [Abstract]
Long-term Debt	The Company's debt obligations consisted of the following: (in millions) Maturity by Fiscal Year July 26, 2019 April 26, 2019 Current debt obligations 2020 $ 1,458 $ 838 Long-term debt 0.000 percent two-year 2019 senior notes 2021 1,673 1,681 Floating rate two-year 2019 senior notes 2021 836 560 4.125 percent ten-year 2011 senior notes 2021 — 500 3.150 percent seven-year 2015 senior notes 2022 1,534 2,500 3.125 percent ten-year 2012 senior notes 2022 — 675 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 0.375 percent four-year 2019 senior notes 2023 1,673 1,681 2.750 percent ten-year 2013 senior notes 2023 531 530 0.000 percent four-year 2019 senior notes 2023 836 — 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 432 850 3.500 percent ten-year 2015 senior notes 2025 2,700 4,000 0.250 percent seven-year 2019 senior notes 2026 1,115 — 1.125 percent eight-year 2019 senior notes 2027 1,673 1,681 3.350 percent ten-year 2017 senior notes 2027 368 850 1.625 percent twelve-year 2019 senior notes 2031 1,115 1,121 1.000 percent thirteen-year 2019 senior notes 2032 1,115 — 4.375 percent twenty-year 2015 senior notes 2035 1,933 2,382 6.550 percent thirty-year 2007 CIFSA senior notes 2038 253 284 2.250 percent twenty-year 2019 senior notes 2039 1,115 1,121 6.500 percent thirty-year 2009 senior notes 2039 158 183 5.550 percent thirty-year 2010 senior notes 2040 224 306 1.500 percent twenty-year 2019 senior notes 2040 1,115 — 4.500 percent thirty-year 2012 senior notes 2042 105 129 4.000 percent thirty-year 2013 senior notes 2043 305 325 4.625 percent thirty-year 2014 senior notes 2044 127 177 4.625 percent thirty-year 2015 senior notes 2045 1,813 1,963 1.750 percent thirty-year 2019 senior notes 2050 1,115 — Bank borrowings 2021 - 2022 80 83 Debt (discount) premium, net 2020 - 2050 (16 ) 29 Finance lease obligations 2021 - 2033 32 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (116 ) (104 ) Long-term debt $ 24,804 $ 24,486

Derivatives and Currency Exch_2

Derivatives and Currency Exchange Risk Management (Tables)	3 Months Ended
	Jul. 26, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the gains (losses) in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) Classification July 26, 2019 July 27, 2018 Currency exchange rate contracts Other operating (income) expense, net $ (6 ) $ 130 Total return swaps Other operating (income) expense, net 5 11 Total $ (1 ) $ 141
Amounts of Gains (Losses) Recognized in AOCI	The amount of the gains (losses) recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Currency exchange rate contracts $ 27 $ 270
Amount and Location of Gains (Losses) in Statements of Income	The amount of the gains (losses) recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended July 26, 2019 July 27, 2018 (in millions) Other operating (income) expense, net Other operating (income) expense, net Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow hedges are recorded $ (22 ) $ 151 Currency exchange rate contracts designated as cash flow hedges: Amount of gain (loss) reclassified from AOCI into income 57 (3 )
Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges	The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet July 26, 2019 April 26, 2019 July 26, 2019 April 26, 2019 Long-term debt $ — $ (1,175 ) $ — $ 9
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Designated as Net Investment Hedges	The amount and classifications of the gains recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended (in millions) Classification July 26, 2019 July 27, 2018 Net investment hedges Other operating (income) expense, net $ (7 ) $ —
Amounts of Gains (Losses) Recognized in AOCI for Net Investment Hedges	The amount of the gains recognized in AOCI related to instruments designated as net investment hedges for the three months ended July 26, 2019 and July 27, 2018 were as follows: Three months ended (in millions) July 26, 2019 July 27, 2018 Net investment hedges $ 99 $ —
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at July 26, 2019 and April 26, 2019 . The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. July 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 212 Other accrued expenses $ 8 Currency exchange rate contracts Other assets 80 Other liabilities 4 Total derivatives designated as hedging instruments 292 12 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 16 Other accrued expenses 21 Total return swap Other current assets 5 Other accrued expenses — Cross currency interest rate contracts Other current assets 5 Other accrued expenses — Total derivatives not designated as hedging instruments 26 21 Total derivatives $ 318 $ 33 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. July 26, 2019 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 308 $ 10 $ 335 $ 30 Derivative liabilities 33 — 19 —
Offsetting Assets	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 308 $ (19 ) $ (5 ) $ 284 Total return swaps 5 — — 5 Cross currency interest rate contracts 5 — — 5 318 (19 ) (5 ) 294 Derivative liabilities: Currency exchange rate contracts (33 ) 19 — (14 ) Total return swaps — — — — (33 ) 19 — (14 ) Total $ 285 $ — $ (5 ) $ 280 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9 ) $ (43 ) $ 283 Interest rate contracts 9 — (1 ) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9 ) (44 ) 312 Derivative liabilities: Currency exchange rate contracts (19 ) 9 — (10 ) (19 ) 9 — (10 ) Total $ 346 $ — $ (44 ) $ 302
Offsetting Liabilities	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 308 $ (19 ) $ (5 ) $ 284 Total return swaps 5 — — 5 Cross currency interest rate contracts 5 — — 5 318 (19 ) (5 ) 294 Derivative liabilities: Currency exchange rate contracts (33 ) 19 — (14 ) Total return swaps — — — — (33 ) 19 — (14 ) Total $ 285 $ — $ (5 ) $ 280 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9 ) $ (43 ) $ 283 Interest rate contracts 9 — (1 ) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9 ) (44 ) 312 Derivative liabilities: Currency exchange rate contracts (19 ) 9 — (10 ) (19 ) 9 — (10 ) Total $ 346 $ — $ (44 ) $ 302

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Jul. 26, 2019
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances, net of reserves, were as follows: (in millions) July 26, 2019 April 26, 2019 Finished goods $ 2,628 $ 2,476 Work in-process 569 572 Raw materials 735 705 Total $ 3,932 $ 3,753

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Jul. 26, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table presents the changes in the carrying of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — — 65 — 65 Purchase accounting adjustments 6 1 (2 ) — 5 Currency translation and other 6 56 (9 ) — 53 July 26, 2019 $ 6,866 $ 20,438 $ 10,875 $ 1,903 $ 40,082
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: July 26, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,968 $ (4,337 ) $ 16,944 $ (4,095 ) Purchased technology and patents 10,792 (4,059 ) 11,405 (4,570 ) Trademarks and tradenames 464 (220 ) 570 (324 ) Other 74 (51 ) 85 (59 ) Total $ 28,298 $ (8,667 ) $ 29,004 $ (9,048 ) Indefinite-lived: IPR&D $ 603 $ — $ 604 $ —
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: July 26, 2019 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,968 $ (4,337 ) $ 16,944 $ (4,095 ) Purchased technology and patents 10,792 (4,059 ) 11,405 (4,570 ) Trademarks and tradenames 464 (220 ) 570 (324 ) Other 74 (51 ) 85 (59 ) Total $ 28,298 $ (8,667 ) $ 29,004 $ (9,048 ) Indefinite-lived: IPR&D $ 603 $ — $ 604 $ —
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at July 26, 2019 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 1,315 2021 1,738 2022 1,698 2023 1,630 2024 1,593 2025 1,560

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Jul. 26, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended (in millions, except per share data) July 26, 2019 July 27, 2018 Numerator: Net income attributable to ordinary shareholders $ 864 $ 1,075 Denominator: Basic – weighted average shares outstanding 1,340.8 1,352.7 Effect of dilutive securities: Employee stock options 6.9 8.4 Employee restricted stock units 3.5 3.6 Other 0.7 0.7 Diluted – weighted average shares outstanding 1,351.9 1,365.4 Basic earnings per share $ 0.64 $ 0.79 Diluted earnings per share $ 0.64 $ 0.79

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Jul. 26, 2019
Share-based Payment Arrangement [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three months ended July 26, 2019 and July 27, 2018 : Three months ended (in millions) July 26, 2019 July 27, 2018 Stock options $ 9 $ 18 Restricted stock 42 36 Employee stock purchase plan 10 10 Total stock-based compensation expense $ 61 $ 64 Cost of products sold $ 6 $ 6 Research and development expense 7 8 Selling, general, and administrative expense 48 50 Total stock-based compensation expense 61 64 Income tax benefits (10 ) (11 ) Total stock-based compensation expense, net of tax $ 51 $ 53

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	3 Months Ended
	Jul. 26, 2019
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 26, 2019 and July 27, 2018 : U.S. Non-U.S. Three months ended Three months ended (in millions) July 26, 2019 July 27, 2018 July 26, 2019 July 27, 2018 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56 ) (54 ) (15 ) (14 ) Amortization of net actuarial loss 14 19 3 3 Net periodic benefit cost $ 16 $ 25 $ 10 $ 11

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jul. 26, 2019
Leases [Abstract]
Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information	The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use asset and lease liability at July 26, 2019 : (in millions) Balance Sheet Classification July 26, 2019 Right-of-use assets Other assets $ 948 Current liability Other accrued expenses 183 Non-current liability Other liabilities 795 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at July 26, 2019 : July 26, 2019 Weighted-average remaining lease term 7.5 years Weighted-average discount rate 3.0% The following table summarizes the components of our total operating lease cost for the three months ended July 26, 2019 : Three months ended (in millions) July 26, 2019 Operating lease cost $ 55 Short-term lease cost 11 Total operating lease cost $ 66 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for new operating lease liabilities for the three months ended July 26, 2019 : Three months ended (in millions) July 26, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 57 Right-of-use assets obtained in exchange for new operating lease liabilities 49
Maturities of Operating Leases	The following table summarizes the maturities of the Company's operating leases at July 26, 2019 : (in millions) Fiscal Year Operating Leases Remaining 2020 $ 152 2021 184 2022 153 2023 132 2024 111 Thereafter 432 Total expected lease payments 1,164 Less: Imputed interest (186 ) Total lease liability $ 978
Minimum Payments Under Non-Cancelable Operating Leases	As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019 , minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Fiscal Year Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Jul. 26, 2019
Equity [Abstract]
Changes in AOCI by Component	The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45 ) $ (1,383 ) $ (169 ) $ (1,308 ) $ 194 $ (2,711 ) Other comprehensive income before reclassifications 51 66 99 — 26 242 Reclassifications 5 — — 13 (33 ) (15 ) Other comprehensive income (loss) 56 66 99 13 (7 ) 227 July 26, 2019 $ 11 $ (1,317 ) $ (70 ) $ (1,295 ) $ 187 $ (2,484 ) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194 ) $ (11 ) $ (257 ) $ (1,117 ) $ (207 ) $ (1,786 ) Other comprehensive (loss) income before reclassifications — (824 ) — — 209 (615 ) Reclassifications — — — 27 4 31 Other comprehensive (loss) income — (824 ) — 27 213 (584 ) Cumulative effect of change in accounting principle (1) 47 — — — — 47 July 27, 2018 $ (147 ) $ (835 ) $ (257 ) $ (1,090 ) $ 6 $ (2,323 ) (1) The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $ 47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Jul. 26, 2019
Segment Reporting [Abstract]
Net Sales by Segment	The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) (in millions) July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 2,790 $ 2,811 Minimally Invasive Therapies Group 2,100 2,052 Restorative Therapies Group 2,012 1,949 Diabetes Group 592 572 Total $ 7,493 $ 7,384 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Segment Operating Profit Three months ended (in millions) July 26, 2019 July 27, 2018 Cardiac and Vascular Group $ 1,055 $ 1,049 Minimally Invasive Therapies Group 771 776 Restorative Therapies Group 793 766 Diabetes Group 149 172 Segment operating profit 2,768 2,763 Interest expense (609 ) (242 ) Other non-operating income, net 101 186 Amortization of intangible assets (440 ) (446 ) Corporate (307 ) (303 ) Centralized distribution costs (345 ) (446 ) Restructuring and associated costs (124 ) (113 ) Acquisition-related items (19 ) (36 ) Certain litigation charges (47 ) (103 ) Exit of businesses — (80 ) Debt tender premium and other charges 7 — Medical device regulations (8 ) — Income before income taxes $ 977 $ 1,180
Net Sales to External Customers by Geography	The following table presents net sales for the three months ended July 26, 2019 and July 27, 2018 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended (in millions) July 26, 2019 July 27, 2018 Ireland $ 20 $ 22 United States 3,918 3,864 Rest of world 3,555 3,498 Total other countries, excluding Ireland 7,473 7,362 Total $ 7,493 $ 7,384

Guarantor Financial Informati_2

Guarantor Financial Information (Tables)	3 Months Ended
	Jul. 26, 2019
Condensed Financial Information Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 426 $ — $ 7,493 $ (426 ) $ 7,493 Costs and expenses: Cost of products sold — 326 — 2,351 (311 ) 2,366 Research and development expense — 168 — 419 — 587 Selling, general, and administrative expense 2 378 — 2,163 — 2,543 Amortization of intangible assets — 3 — 437 — 440 Restructuring charges, net — 3 — 44 — 47 Certain litigation charges — 5 — 42 — 47 Other operating expense (income), net 13 (439 ) (7 ) 500 (89 ) (22 ) Operating profit (loss) (15 ) (18 ) 7 1,537 (26 ) 1,485 Other non-operating (income) expense, net — (61 ) (245 ) (404 ) 609 (101 ) Interest expense 145 712 164 197 (609 ) 609 Equity in net (income) loss of subsidiaries (1,022 ) (610 ) (934 ) — 2,566 — Income (loss) before income taxes 862 (59 ) 1,022 1,744 (2,592 ) 977 Income tax (benefit) provision (2 ) (129 ) — 231 — 100 Net income (loss) 864 70 1,022 1,513 (2,592 ) 877 Net income attributable to noncontrolling interests — — — (13 ) — (13 ) Net income (loss) attributable to Medtronic 864 70 1,022 1,500 (2,592 ) 864 Other comprehensive income (loss), net of tax 227 46 227 108 (381 ) 227 Comprehensive income attributable to noncontrolling interests — — — (13 ) — (13 ) Total comprehensive income (loss) $ 1,091 $ 116 $ 1,249 $ 1,608 $ (2,973 ) $ 1,091 Consolidating Statement of Comprehensive Income Three Months Ended July 27, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 362 $ — $ 7,384 $ (362 ) $ 7,384 Costs and expenses: Cost of products sold — 273 — 2,168 (237 ) 2,204 Research and development expense — 168 — 417 — 585 Selling, general, and administrative expense 3 366 — 2,228 — 2,597 Amortization of intangible assets — 2 — 444 — 446 Restructuring charges, net — 10 — 52 — 62 Certain litigation charges — 78 — 25 — 103 Other operating expense (income), net — (259 ) — 511 (101 ) 151 Operating profit (loss) (3 ) (276 ) — 1,539 (24 ) 1,236 Other non-operating (income) expense, net — (160 ) (164 ) (504 ) 642 (186 ) Interest expense 99 465 103 217 (642 ) 242 Equity in net (income) loss of subsidiaries (1,175 ) (814 ) (1,114 ) — 3,103 — Income (loss) before income taxes 1,073 233 1,175 1,826 (3,127 ) 1,180 Income tax (benefit) provision (2 ) (104 ) — 209 — 103 Net income (loss) 1,075 337 1,175 1,617 (3,127 ) 1,077 Net income attributable to noncontrolling interests — — — (2 ) — (2 ) Net income (loss) attributable to Medtronic 1,075 337 1,175 1,615 (3,127 ) 1,075 Other comprehensive (loss) income, net of tax (584 ) (507 ) (584 ) (604 ) 1,695 (584 ) Comprehensive loss attributable to noncontrolling interests — — — (2 ) — (2 ) Total comprehensive income (loss) $ 491 $ (170 ) $ 591 $ 1,011 $ (1,432 ) $ 491 Consolidating Statement of Comprehensive Income Three Months Ended July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,493 $ — $ 7,493 Costs and expenses: Cost of products sold — — — 2,366 — 2,366 Research and development expense — — — 587 — 587 Selling, general, and administrative expense 2 — — 2,541 — 2,543 Amortization of intangible assets — — — 440 — 440 Restructuring charges, net — — — 47 — 47 Certain litigation charges — — — 47 — 47 Other operating expense (income), net 13 — (7 ) (28 ) — (22 ) Operating profit (loss) (15 ) — 7 1,493 — 1,485 Other non-operating (income) expense, net — (63 ) (253 ) (397 ) 612 (101 ) Interest expense 145 221 165 690 (612 ) 609 Equity in net (income) loss of subsidiaries (1,022 ) (968 ) (927 ) — 2,917 — Income (loss) before income taxes 862 810 1,022 1,200 (2,917 ) 977 Income tax (benefit) provision (2 ) — — 102 — 100 Net income (loss) 864 810 1,022 1,098 (2,917 ) 877 Net income attributable to noncontrolling interests — — — (13 ) — (13 ) Net income (loss) attributable to Medtronic 864 810 1,022 1,085 (2,917 ) 864 Other comprehensive income (loss), net of tax 227 84 227 128 (439 ) 227 Comprehensive income attributable to noncontrolling interests — — — (13 ) — (13 ) Total comprehensive income (loss) $ 1,091 $ 894 $ 1,249 $ 1,213 $ (3,356 ) $ 1,091 Consolidating Statement of Comprehensive Income Three Months Ended July 27, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,384 $ — $ 7,384 Costs and expenses: Cost of products sold — — — 2,204 — 2,204 Research and development expense — — — 585 — 585 Selling, general, and administrative expense 3 — 1 2,593 — 2,597 Amortization of intangible assets — — — 446 — 446 Restructuring charges, net — — — 62 — 62 Certain litigation charges — — — 103 — 103 Other operating expense, net — — — 146 5 151 Operating profit (loss) (3 ) — (1 ) 1,245 (5 ) 1,236 Other non-operating (income) expense, net — (11 ) (170 ) (273 ) 268 (186 ) Interest expense 99 21 103 287 (268 ) 242 Equity in net (income) loss of subsidiaries (1,175 ) (972 ) (1,109 ) — 3,256 — Income (loss) before income taxes 1,073 962 1,175 1,231 (3,261 ) 1,180 Income tax (benefit) provision (2 ) — — 105 — 103 Net income (loss) 1,075 962 1,175 1,126 (3,261 ) 1,077 Net income attributable to noncontrolling interests — — — (2 ) — (2 ) Net income (loss) attributable to Medtronic 1,075 962 1,175 1,124 (3,261 ) 1,075 Other comprehensive (loss) income, net of tax (584 ) (40 ) (584 ) (584 ) 1,208 (584 ) Comprehensive loss attributable to — — — (2 ) — (2 ) Total comprehensive income (loss) $ 491 $ 922 $ 591 $ 540 $ (2,053 ) $ 491
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 15 $ 93 $ 4,972 $ — $ 5,080 Investments — — — 5,603 — 5,603 Accounts receivable, net — — — 5,894 — 5,894 Inventories, net — 184 — 3,998 (250 ) 3,932 Intercompany receivable 80 9,837 5 30,756 (40,678 ) — Other current assets 16 212 3 1,965 — 2,196 Total current assets 96 10,248 101 53,188 (40,928 ) 22,705 Property, plant, and equipment, net — 1,508 — 3,203 — 4,711 Goodwill — 2,009 — 38,073 — 40,082 Other intangible assets, net — 96 — 20,138 — 20,234 Tax assets — 494 — 1,051 — 1,545 Investment in subsidiaries 65,549 72,421 66,048 — (204,018 ) — Intercompany loans receivable 3,000 21 29,017 25,238 (57,276 ) — Other assets — 308 — 1,683 — 1,991 Total assets $ 68,645 $ 87,105 $ 95,166 $ 142,574 $ (302,222 ) $ 91,268 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,033 $ — $ 425 $ — $ 1,458 Accounts payable — 492 — 1,414 — 1,906 Intercompany payable — 21,093 9,662 9,923 (40,678 ) — Accrued compensation 12 532 — 963 — 1,507 Accrued income taxes — — — 500 — 500 Other accrued expenses 20 467 39 2,621 — 3,147 Total current liabilities 32 23,617 9,701 15,846 (40,678 ) 8,518 Long-term debt — 9,780 13,601 1,423 — 24,804 Accrued compensation and retirement benefits — 1,070 — 570 — 1,640 Accrued income taxes 10 709 — 2,154 — 2,873 Intercompany loans payable 18,240 9,011 13,320 16,705 (57,276 ) — Deferred tax liabilities — — — 1,346 — 1,346 Other liabilities — 223 — 1,367 — 1,590 Total liabilities 18,282 44,410 36,622 39,411 (97,954 ) 40,771 Shareholders’ equity 50,363 42,695 58,544 103,029 (204,268 ) 50,363 Noncontrolling interests — — — 134 — 134 Total equity 50,363 42,695 58,544 103,163 (204,268 ) 50,497 Total liabilities and equity $ 68,645 $ 87,105 $ 95,166 $ 142,574 $ (302,222 ) $ 91,268 Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227 ) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623 ) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850 ) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,129 65,012 — (200,493 ) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277 ) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620 ) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623 ) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623 ) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277 ) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900 ) 39,482 Shareholders' equity 50,091 42,204 57,324 101,192 (200,720 ) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,204 57,324 101,313 (200,720 ) 50,212 Total liabilities and equity $ 67,402 $ 85,325 $ 92,880 $ 139,707 $ (295,620 ) $ 89,694 Condensed Consolidating Balance Sheet July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 93 $ 4,987 $ — $ 5,080 Investments — — — 5,603 — 5,603 Accounts receivable, net — — — 5,894 — 5,894 Inventories, net — — — 3,932 — 3,932 Intercompany receivable 80 — 1,381 9,690 (11,151 ) — Other current assets 16 — 3 2,177 — 2,196 Total current assets 96 — 1,477 32,283 (11,151 ) 22,705 Property, plant, and equipment, net — — — 4,711 — 4,711 Goodwill — — — 40,082 — 40,082 Other intangible assets, net — — — 20,234 — 20,234 Tax assets — — — 1,545 — 1,545 Investment in subsidiaries 65,549 57,719 64,661 — (187,929 ) — Intercompany loans receivable 3,000 3,989 29,017 40,447 (76,453 ) — Other assets — — — 1,991 — 1,991 Total assets $ 68,645 $ 61,708 $ 95,155 $ 141,293 $ (275,533 ) $ 91,268 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 1,458 $ — $ 1,458 Accounts payable — — — 1,906 — 1,906 Intercompany payable — 1,316 9,662 173 (11,151 ) — Accrued compensation 12 — — 1,495 — 1,507 Accrued income taxes — — — 500 — 500 Other accrued expenses 20 8 44 3,075 — 3,147 Total current liabilities 32 1,324 9,706 8,607 (11,151 ) 8,518 Long-term debt — 1,311 13,601 9,892 — 24,804 Accrued compensation and retirement benefits — — — 1,640 — 1,640 Accrued income taxes 10 — — 2,863 — 2,873 Intercompany loans payable 18,240 27,127 13,320 17,766 (76,453 ) — Deferred tax liabilities — — — 1,346 — 1,346 Other liabilities — — 1 1,589 — 1,590 Total liabilities 18,282 29,762 36,628 43,703 (87,604 ) 40,771 Shareholders’ equity 50,363 31,946 58,527 97,456 (187,929 ) 50,363 Noncontrolling interests — — — 134 — 134 Total equity 50,363 31,946 58,527 97,590 (187,929 ) 50,497 Total liabilities and equity $ 68,645 $ 61,708 $ 95,155 $ 141,293 $ (275,533 ) $ 91,268 Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626 ) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626 ) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,557 63,651 — (167,560 ) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979 ) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165 ) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626 ) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626 ) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979 ) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605 ) 39,482 Shareholders' equity 50,091 31,683 57,324 78,553 (167,560 ) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,683 57,324 78,674 (167,560 ) 50,212 Total liabilities and equity $ 67,402 $ 43,676 $ 92,887 $ 125,894 $ (240,165 ) $ 89,694
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Three Months Ended July 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ (115 ) $ (803 ) $ 150 $ 2,278 $ — $ 1,510 Investing Activities: Acquisitions, net of cash acquired — — — (145 ) — (145 ) Additions to property, plant, and equipment — (74 ) — (227 ) — (301 ) Purchases of investments — — — (1,669 ) — (1,669 ) Sales and maturities of investments — — — 1,569 — 1,569 Other investing activities — — (5 ) — — (5 ) Net cash provided by (used in) investing activities — (74 ) (5 ) (472 ) — (551 ) Financing Activities: Change in current debt obligations, net — — — 88 — 88 Issuance of long-term debt — — 5,567 — — 5,567 Payments on long-term debt — (4,463 ) (515 ) (57 ) — (5,035 ) Dividends to shareholders (724 ) — — — — (724 ) Issuance of ordinary shares 210 — — — — 210 Repurchase of ordinary shares (333 ) — — — — (333 ) Net intercompany loan borrowings (repayments) 962 5,337 (5,058 ) (1,241 ) — — Other financing activities — — (47 ) — — (47 ) Net cash provided by (used in) financing activities 115 874 (53 ) (1,210 ) — (274 ) Effect of exchange rate changes on cash and cash equivalents — — — 2 — 2 Net change in cash and cash equivalents — (3 ) 92 598 — 687 Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ 15 $ 93 $ 4,972 $ — $ 5,080 Condensed Consolidating Statement of Cash Flows Three Months Ended July 27, 2018 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (6 ) $ (387 ) $ 72 $ 2,023 $ — $ 1,702 Investing Activities: Acquisitions, net of cash acquired — — — (104 ) — (104 ) Additions to property, plant, and equipment — (49 ) — (242 ) — (291 ) Purchases of investments — — — (982 ) — (982 ) Sales and maturities of investments — 76 — 1,944 — 2,020 Capital contribution paid — (32 ) — — 32 — Net cash provided by (used in) investing activities — (5 ) — 616 32 643 Financing Activities: Change in current debt obligations, net — — (472 ) (33 ) — (505 ) Payments on long-term debt — — — (12 ) — (12 ) Dividends to shareholders (677 ) — — — — (677 ) Issuance of ordinary shares 450 — — — — 450 Repurchase of ordinary shares (824 ) — — — — (824 ) Net intercompany loan borrowings (repayments) 1,057 396 789 (2,242 ) — — Capital contribution received — — — 32 (32 ) — Other financing activities — — — (5 ) — (5 ) Net cash provided by (used in) financing activities 6 396 317 (2,260 ) (32 ) (1,573 ) Effect of exchange rate changes on cash and cash equivalents — — — (61 ) — (61 ) Net change in cash and cash equivalents — 4 389 318 — 711 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 24 $ 390 $ 3,966 $ — $ 4,380 Condensed Consolidating Statement of Cash Flows Three Months Ended July 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (115 ) $ (161 ) $ 157 $ 1,629 $ — $ 1,510 Investing Activities: Acquisitions, net of cash acquired — — — (145 ) — (145 ) Additions to property, plant, and equipment — — — (301 ) — (301 ) Purchases of investments — — — (1,669 ) — (1,669 ) Sales and maturities of investments — — — 1,569 — 1,569 Capital contribution paid — (6 ) — — 6 — Other investing activities — — (5 ) — — (5 ) Net cash provided by (used in) investing activities — (6 ) (5 ) (546 ) 6 (551 ) Financing Activities: Change in current debt obligations, net — — — 88 — 88 Issuance of long-term debt — — 5,567 — — 5,567 Payments on long-term debt — (44 ) (515 ) (4,476 ) — (5,035 ) Dividends to shareholders (724 ) — — — — (724 ) Issuance of ordinary shares 210 — — — — 210 Repurchase of ordinary shares (333 ) — — — — (333 ) Net intercompany loan borrowings (repayments) 962 211 (5,065 ) 3,892 — — Capital contribution received — — — 6 (6 ) — Other financing activities — — (47 ) — — (47 ) Net cash provided by (used in) financing activities 115 167 (60 ) (490 ) (6 ) (274 ) Effect of exchange rate changes on cash and cash equivalents — — — 2 — 2 Net change in cash and cash equivalents — — 92 595 — 687 Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 93 $ 4,987 $ — $ 5,080 Condensed Consolidating Statement of Cash Flows Three Months Ended July 27, 2018 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (6 ) $ (24 ) $ 77 $ 1,655 $ — $ 1,702 Investing Activities: Acquisitions, net of cash acquired — — — (104 ) — (104 ) Additions to property, plant, and equipment — — — (291 ) — (291 ) Purchases of investments — — — (982 ) — (982 ) Sales and maturities of investments — — — 2,020 — 2,020 Capital contributions paid — (185 ) — — 185 — Net cash provided by (used in) investing activities — (185 ) — 643 185 643 Financing Activities: Change in current debt obligations, net — — (473 ) (32 ) — (505 ) Payments on long-term debt — — — (12 ) — (12 ) Dividends to shareholders (677 ) — — — — (677 ) Issuance of ordinary shares 450 — — — — 450 Repurchase of ordinary shares (824 ) — — — — (824 ) Net intercompany loan borrowings (repayments) 1,057 209 785 (2,051 ) — — Capital contributions received — — — 185 (185 ) — Other financing activities — — — (5 ) — (5 ) Net cash provided by (used in) financing activities 6 209 312 (1,915 ) (185 ) (1,573 ) Effect of exchange rate changes on cash and cash equivalents — — — (61 ) — (61 ) Net change in cash and cash equivalents — — 389 322 — 711 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 390 $ 3,990 $ — $ 4,380

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 27, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets	$ 948
Total lease liability	$ 978
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets		$ 1,000
Total lease liability		$ 1,000

Revenue - Disaggregation of Ne

Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 7,493	$ 7,384
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,790	2,811
Cardiac and Vascular Group | Cardiac Rhythm & Heart Failure
Disaggregation of Revenue [Line Items]
Net sales	1,382	1,426
Cardiac and Vascular Group | Coronary & Structural Heart
Disaggregation of Revenue [Line Items]
Net sales	941	917
Cardiac and Vascular Group | Aortic, Peripheral, & Venous
Disaggregation of Revenue [Line Items]
Net sales	467	468
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,100	2,052
Minimally Invasive Therapies Group | Surgical Innovations
Disaggregation of Revenue [Line Items]
Net sales	1,417	1,397
Minimally Invasive Therapies Group | Respiratory, Gastrointestinal, & Renal
Disaggregation of Revenue [Line Items]
Net sales	683	655
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,012	1,949
Restorative Therapies Group | Brain Therapies
Disaggregation of Revenue [Line Items]
Net sales	740	674
Restorative Therapies Group | Spine
Disaggregation of Revenue [Line Items]
Net sales	658	652
Restorative Therapies Group | Specialty Therapies
Disaggregation of Revenue [Line Items]
Net sales	322	309
Restorative Therapies Group | Pain Therapies
Disaggregation of Revenue [Line Items]
Net sales	292	314
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	$ 592	$ 572

Revenue - Disaggregation of Net

Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 7,493	$ 7,384
U.S.
Disaggregation of Revenue [Line Items]
Net sales	3,918	3,864
Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,377	2,406
Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	1,198	1,114
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,790	2,811
Cardiac and Vascular Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,361	1,389
Cardiac and Vascular Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	930	947
Cardiac and Vascular Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	499	475
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,100	2,052
Minimally Invasive Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	913	857
Minimally Invasive Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	791	828
Minimally Invasive Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	396	367
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,012	1,949
Restorative Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,338	1,294
Restorative Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	426	428
Restorative Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	248	227
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	592	572
Diabetes Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	306	324
Diabetes Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	231	203
Diabetes Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 55	$ 45

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Apr. 26, 2019
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 295	$ 315
Revenue recognized that was previously included in deferred revenue	98
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations	$ 1,000
Period over which remaining performance obligations are expected to be recognized as revenue	four years
Other accrued expenses
Disaggregation of Revenue [Line Items]
Rebate obligations	$ 761	764
Deferred revenue	195	211
Reduction of accounts receivable
Disaggregation of Revenue [Line Items]
Rebate obligations	426	432
Other liabilities
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 100	$ 104

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018	Apr. 26, 2019	Apr. 27, 2018
Business Acquisition [Line Items]
Goodwill	$ 40,082		$ 39,959
Contingent consideration liabilities in connection with business combinations	58	$ 35
Purchase accounting adjustments. increase to goodwill	5
Contingent consideration liabilities	269	208	222	$ 173
Other accrued expenses
Business Acquisition [Line Items]
Contingent consideration liabilities	64		73
Other liabilities
Business Acquisition [Line Items]
Contingent consideration liabilities	205		$ 149
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Net assets acquired	206	150
Total assets acquired	247	171
Total liabilities assumed	41	21
Inventory	40
Goodwill	65	62
Contingent consideration liabilities in connection with business combinations	58
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	$ 91	$ 93
Estimated useful life	8 years
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life		14 years
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life		15 years
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	$ 26
Estimated useful life	8 years
Mazor Robotics and EPiX Therapeutics, Inc
Business Acquisition [Line Items]
Purchase accounting adjustments. increase to goodwill	$ 5

Acquisitions - Reconciliation o

Acquisitions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning balance	$ 222	$ 173
Purchase price contingent consideration	58	35
Payments	(14)	(6)
Change in fair value	3	6
Ending balance	$ 269	$ 208

Acquisitions - Fair Value Measu

Acquisitions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) $ in Millions	Jul. 26, 2019USD ($)	Apr. 26, 2019USD ($)	Jul. 27, 2018USD ($)	Apr. 27, 2018USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 269	$ 222	$ 208	$ 173
Revenue and other performance-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 135
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.115
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.40
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.325
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1
Product development and other milestone-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 134
Product development and other milestone-based payments | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.055
Product development and other milestone-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.75
Product development and other milestone-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Restructuring Cost and Reserve [Line Items]
Charges	$ 136	$ 120
Accrual adjustments	12
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges	35	15
Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Charges	42	$ 36
Minimum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	1,600
Maximum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	$ 1,800

Restructuring - Termination Lia

Restructuring - Termination Liability and Restructuring Reserve (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Restructuring Reserve [Roll Forward]
Beginning balance	$ 122
Charges	136	$ 120
Cash payments	(127)
Settled non-cash	(6)
Accrual adjustments	(12)
Ending balance	113
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance	101
Charges	52
Cash payments	(58)
Settled non-cash	0
Accrual adjustments	(5)
Ending balance	90
Associated Costs
Restructuring Reserve [Roll Forward]
Beginning balance	9
Charges	71
Cash payments	(62)
Settled non-cash	0
Accrual adjustments	0
Ending balance	18
Asset Write-Downs
Restructuring Reserve [Roll Forward]
Beginning balance	0
Charges	6
Cash payments	0
Settled non-cash	(6)
Accrual adjustments	0
Ending balance	0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance	12
Charges	7
Cash payments	(7)
Settled non-cash	0
Accrual adjustments	(7)
Ending balance	$ 5

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Schedule of Investments [Line Items]
Cost	$ 5,633	$ 5,540
Unrealized Gains	49	20
Unrealized Losses	(35)	(61)
Fair Value	5,647	5,499
Investments
Schedule of Investments [Line Items]
Fair Value	5,603	5,455
Other Assets
Schedule of Investments [Line Items]
Fair Value	44	44
Level 2
Schedule of Investments [Line Items]
Cost	5,037	4,964
Unrealized Gains	41	19
Unrealized Losses	(32)	(51)
Fair Value	5,046	4,932
Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	5,046	4,932
Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Corporate debt securities | Level 2
Schedule of Investments [Line Items]
Cost	3,123	3,500
Unrealized Gains	30	14
Unrealized Losses	(13)	(21)
Fair Value	3,140	3,493
Corporate debt securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	3,140	3,493
Corporate debt securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 1
Schedule of Investments [Line Items]
Cost	549	529
Unrealized Gains	8	1
Unrealized Losses	0	(7)
Fair Value	557	523
U.S. government and agency securities | Level 1 | Investments
Schedule of Investments [Line Items]
Fair Value	557	523
U.S. government and agency securities | Level 1 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	788	387
Unrealized Gains	0	1
Unrealized Losses	(2)	(7)
Fair Value	786	381
U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	786	381
U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Mortgage-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	578	537
Unrealized Gains	8	3
Unrealized Losses	(14)	(20)
Fair Value	572	520
Mortgage-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	572	520
Mortgage-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Non-U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	11	11
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	11	11
Non-U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	11	11
Non-U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Other asset-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	537	529
Unrealized Gains	3	1
Unrealized Losses	(3)	(3)
Fair Value	537	527
Other asset-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	537	527
Other asset-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3
Schedule of Investments [Line Items]
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities | Level 3 | Investments
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Schedule of Investments [Line Items]
Fair Value	$ 44	$ 44

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	$ 872	$ 1,075
Less than 12 months, Unrealized Losses	(11)	(9)
More than 12 months, Fair Value	951	2,181
More than 12 months, Unrealized Losses	(24)	(52)
U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	62	130
Less than 12 months, Unrealized Losses	0	(1)
More than 12 months, Fair Value	311	649
More than 12 months, Unrealized Losses	(2)	(13)
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	535	582
Less than 12 months, Unrealized Losses	(8)	(5)
More than 12 months, Fair Value	371	1,153
More than 12 months, Unrealized Losses	(5)	(16)
Mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	79	73
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	113	250
More than 12 months, Unrealized Losses	(13)	(19)
Non-U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	3
Less than 12 months, Unrealized Losses	0
More than 12 months, Fair Value	0
More than 12 months, Unrealized Losses	0
Other asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	193	290
Less than 12 months, Unrealized Losses	(2)	(2)
More than 12 months, Fair Value	112	85
More than 12 months, Unrealized Losses	(1)	(1)
Auction rate securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	$ (3)	$ (3)

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018	Apr. 26, 2019
Activities Related to Investment Portfolio
Proceeds from sales	$ 1,567	$ 1,112
Gross realized gains	4	6
Gross realized losses	(8)	$ (7)
AFS Debt Maturities
Due in one year or less	1,157
Due after one year through five years	2,407
Due after five years through ten years	2,030
Due after ten years	53
Fair Value	$ 5,647		$ 5,499

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018	Apr. 26, 2019
Investments [Abstract]
Credit loss portion of other-than-temporary impairments	$ 0		$ 0
Reductions for available-for-sale securities sold	0	$ 0
Gain (Loss) on Securities [Line Items]
Net gains (losses) recognized	$ 0
Equity and Other Investments
Gain (Loss) on Securities [Line Items]
Net gains (losses) recognized		98,000,000
Net realized gains on equity and other investments sold during the period		45,000,000
Net unrealized gains on equity and other investments still held		$ 53,000,000

Financial Instruments - Summary

Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Investment [Line Items]
Investments without readily determinable fair values	$ 308	$ 308
Equity method and other investments	64	64
Total equity and other investments	$ 372	$ 372

Financial Instruments - Activ_2

Financial Instruments - Activity Related to the Company's Investment Portfolio, Equity and Other Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Investment [Line Items]
Proceeds from sales	$ 1,569	$ 2,020
Equity and Other Investments
Investment [Line Items]
Proceeds from sales	2	908
Gross gains	0	114
Gross losses	0	(16)
Recognized impairment losses	$ (1)	$ 0

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details)	Dec. 12, 2018USD ($)	Aug. 30, 2019USD ($)	Jul. 26, 2019USD ($)	Jun. 30, 2019USD ($)	Jul. 26, 2019USD ($)	Jul. 27, 2018USD ($)	Jun. 30, 2019EUR (€)tranche	Apr. 26, 2019USD ($)
Senior Notes
Principal value			$ 25,900,000,000		$ 25,900,000,000			$ 25,000,000,000
Cash proceeds, net of discounts and issuance costs					5,567,000,000	$ 0
Loss on extinguishment of debt					406,000,000	$ 0
Financial Instruments Not Measured at Fair Value
Long-term debt, including the current portion, fair value			27,800,000,000		27,800,000,000			26,200,000,000
Commercial Paper Program | Commercial Paper
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount			3,500,000,000		3,500,000,000
Commercial paper, amount outstanding			0		0			0
Credit Facility | Line of Credit
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000
Term of debt instrument	5 years
Line of credit, amount outstanding			$ 0		$ 0			$ 0
Senior Notes 2019 | Senior notes | Medtronic Luxco
Senior Notes
Number of tranches | tranche							6
Principal value | €							€ 5,000,000,000
Cash proceeds, net of discounts and issuance costs				$ 5,600,000,000
Floating Rate Notes due 2021 | Senior notes
Line of Credit Facility
Term of debt instrument					2 years
Floating Rate Notes due 2021 | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							250,000,000
0.000 percent four-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					4 years
Senior Notes
Stated interest rate			0.00%		0.00%
0.000 percent four-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 750,000,000
Stated interest rate							0.00%
0.250 percent seven-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					7 years
Senior Notes
Stated interest rate			0.25%		0.25%
0.250 percent seven-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							0.25%
1.000 percent thirteen-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					13 years
Senior Notes
Stated interest rate			1.00%		1.00%
1.000 percent thirteen-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.00%
1.500 percent twenty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					20 years
Senior Notes
Stated interest rate			1.50%		1.50%
1.500 percent twenty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.50%
1.750 percent thirty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					30 years
Senior Notes
Stated interest rate			1.75%		1.75%
1.750 percent thirty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.75%
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior notes
Senior Notes
Cash tender offer, amount of outstanding debt			$ 4,600,000,000
Total consideration			$ 5,000,000,000
Loss on extinguishment of debt					$ 413,000,000
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior notes | Subsequent Event
Senior Notes
Cash tender offer, amount of outstanding debt		$ 533,000,000
Early redemption premium		$ 16,000,000

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Apr. 26, 2019
Debt Instrument [Line Items]
Current debt obligations	$ 1,458	$ 838
Long-term debt
Debt (discount) premium, net	(16)	29
Deferred financing costs	(116)	(104)
Long-term debt	$ 24,804	24,486
Senior notes | 0.000 percent two-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	2 years
Long-term debt, gross	$ 1,673	1,681
Senior notes | Floating rate two-year 2019 senior notes
Long-term debt
Term of debt instrument	2 years
Long-term debt, gross	$ 836	560
Senior notes | 4.125 percent ten-year 2011 senior notes
Long-term debt
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	500
Senior notes | 3.150 percent seven-year 2015 senior notes
Long-term debt
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,534	2,500
Senior notes | 3.125 percent ten-year 2012 senior notes
Long-term debt
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	675
Senior notes | 3.200 percent ten-year 2012 CIFSA senior notes
Long-term debt
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 650	650
Senior notes | 0.375 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.375%
Term of debt instrument	4 years
Long-term debt, gross	$ 1,673	1,681
Senior notes | 2.750 percent ten-year 2013 senior notes
Long-term debt
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term debt, gross	$ 531	530
Senior notes | 0.000 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	4 years
Long-term debt, gross	$ 836	0
Senior notes | 2.950 percent ten-year 2013 CIFSA senior notes
Long-term debt
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term debt, gross	$ 310	310
Senior notes | 3.625 percent ten-year 2014 senior notes
Long-term debt
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term debt, gross	$ 432	850
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term debt, gross	$ 2,700	4,000
Senior notes | 0.250 percent seven-year 2019 senior notes
Long-term debt
Stated interest rate	0.25%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,115	0
Senior notes | 1.125 percent eight-year 2019 senior notes
Long-term debt
Stated interest rate	1.125%
Term of debt instrument	8 years
Long-term debt, gross	$ 1,673	1,681
Senior notes | 3.350 percent ten-year 2017 senior notes
Long-term debt
Stated interest rate	3.35%
Term of debt instrument	10 years
Long-term debt, gross	$ 368	850
Senior notes | 1.625 percent twelve-year 2019 senior notes
Long-term debt
Stated interest rate	1.625%
Term of debt instrument	12 years
Long-term debt, gross	$ 1,115	1,121
Senior notes | 1.000 percent thirteen-year 2019 senior notes
Long-term debt
Stated interest rate	1.00%
Term of debt instrument	13 years
Long-term debt, gross	$ 1,115	0
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,933	2,382
Senior notes | 6.550 percent thirty-year 2007 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 253	284
Senior notes | 2.250 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	2.25%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,115	1,121
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 158	183
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 224	306
Senior notes | 1.500 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	1.50%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,115	0
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 105	129
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term debt, gross	$ 305	325
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 127	177
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,813	1,963
Senior notes | 1.750 percent thirty-year 2019 senior notes
Long-term debt
Stated interest rate	1.75%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,115	0
Bank borrowings
Long-term debt
Long-term debt, gross	80	83
Finance lease obligations
Long-term debt
Finance lease obligations	32
Finance lease obligations		10
Interest rate swaps
Long-term debt
Interest rate swaps	$ 0	$ 9

Derivatives and Currency Exch_3

Derivatives and Currency Exchange Risk Management - Narrative (Details) € in Billions	3 Months Ended
	Jul. 26, 2019USD ($)derivative	Jul. 27, 2018USD ($)	Jul. 26, 2019EUR (€)derivative	Apr. 26, 2019USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	$ 187,000,000			$ 194,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months	164,000,000
Debt, face amount	25,900,000,000			25,000,000,000
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	$ 0
After-tax net unrealized gains (losses) associated with net investment hedging instruments recorded in AOCI	(70,000,000)	(169,000,000)
Net investment hedge unrealized gains or losses to be reclassified over the next twelve months, net of tax	0
Gains (losses) on firm commitments that no longer qualify as net investment hedges	$ 0	$ 0
4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	4.125%		4.125%
3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	3.125%		3.125%
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 10,800,000,000			11,100,000,000
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	4,200,000,000			4,300,000,000
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 6,700,000,000			6,800,000,000
Maximum remaining maturity of foreign currency derivatives	2 years
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 13,400,000,000		€ 12
Total return swap | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount	$ 201,000,000			191,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount				1,200,000,000
Number of interest rate swaps outstanding | derivative	0		0
Market value of outstanding interest rate swap agreements - net unrealized gain				9,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount				$ 500,000,000
Stated interest rate				4.125%
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount				$ 675,000,000
Stated interest rate				3.125%

Derivatives and Currency Exch_4

Derivatives and Currency Exchange Risk Management - Derivative Gains (Losses) Not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ (1)	$ 141
Other operating (income) expense, net | Currency exchange rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Total	(6)	130
Other operating (income) expense, net | Total return swap
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 5	$ 11

Derivatives and Currency Exch_5

Derivatives and Currency Exchange Risk Management - Gains (Losses) Recognized in AOCI, Cash Flow Hedges (Details) - Currency exchange rate contracts - Cash flow hedging - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Cash flow hedges	$ 27
Recognized in AOCI, Cash flow hedges		$ 270

Derivatives and Currency Exch_6

Derivatives and Currency Exchange Risk Management - Amount of Gains (Losses) Recognized in Consolidated Statements of Income, Cash Flow Hedges (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Other operating (income) expense, net	$ (22)	$ 151
Cash flow hedging | Currency exchange rate contracts | Other operating (income) expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of gain (loss) reclassified from AOCI into income	$ 57
Amount of gain (loss) reclassified from AOCI into income		$ (3)

Derivatives and Currency Exch_7

Derivatives and Currency Exchange Risk Management - Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges (Details) - Long-term debt - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Carrying Amount of Hedged Assets/(Liabilities)	$ 0	$ (1,175)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities)	$ 0	$ 9

Derivatives and Currency Exch_8

Derivatives and Currency Exchange Risk Management - Gains (Losses) Recognized in Income, Net Investment Hedges (Details) - Currency exchange rate contracts - Other operating (income) expense, net - Net investment hedges - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income, Net investment hedges	$ (7)
Recognized in Income, Net investment hedges		$ 0

Derivatives and Currency Exch_9

Derivatives and Currency Exchange Risk Management - Gains Losses Recognized in AOCI, Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Net investment hedges	$ 99
Recognized in AOCI, Net investment hedges		$ 0
Currency exchange rate contracts | Net investment hedges
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI, Net investment hedges	$ 99
Recognized in AOCI, Net investment hedges		$ 0

Derivatives and Currency Exc_10

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	$ 318	$ 365
Derivative Liabilities, Fair Value	33	19
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	308	335
Derivative Liabilities, Fair Value	33	19
Interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Total return swap
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	5	15
Derivative Liabilities, Fair Value	0
Cross currency interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	5	6
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	292	321
Derivative Liabilities, Fair Value	12	2
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	212	234
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	80	78
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	8	1
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	4	1
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value		0
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	26	44
Derivative Liabilities, Fair Value	21	17
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	16	23
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	21	17
Derivatives not designated as hedging instruments | Total return swap | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	5	15
Derivatives not designated as hedging instruments | Total return swap | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	0	0
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	5	6
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	$ 0	$ 0

Derivatives and Currency Exc_11

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 308	$ 335
Derivative liabilities	33	19
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	10	30
Derivative liabilities	$ 0	$ 0

Derivatives and Currency Exc_12

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	$ 318	$ 365
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(19)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(44)
Net Amount	294	312
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(33)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	19	9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	(14)	(10)
Total
Gross Amount of Recorded Assets (Liabilities)	285	346
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(44)
Net Amount	280	302
Currency exchange rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	308	335
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(19)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(43)
Net Amount	284	283
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(33)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	19	9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	(14)	(10)
Interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)		9
Gross Amount Not Offset on the Balance Sheet, Financial Instruments		0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)		(1)
Net Amount		8
Total return swaps
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	5	15
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	5	15
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	0
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0
Net Amount	0
Cross currency interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	5	6
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	$ 5	$ 6

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 2,628	$ 2,476
Work in-process	569	572
Raw materials	735	705
Total	$ 3,932	$ 3,753

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	3 Months Ended
	Jul. 26, 2019USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 39,959
Goodwill as a result of acquisitions	65
Purchase accounting adjustments	5
Currency translation and other	53
Ending balance	40,082
Cardiac and Vascular Group
Goodwill [Roll Forward]
Beginning balance	6,854
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	6
Currency translation and other	6
Ending balance	6,866
Minimally Invasive Therapies Group
Goodwill [Roll Forward]
Beginning balance	20,381
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	1
Currency translation and other	56
Ending balance	20,438
Restorative Therapies Group
Goodwill [Roll Forward]
Beginning balance	10,821
Goodwill as a result of acquisitions	65
Purchase accounting adjustments	(2)
Currency translation and other	(9)
Ending balance	10,875
Diabetes Group
Goodwill [Roll Forward]
Beginning balance	1,903
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	0
Currency translation and other	0
Ending balance	$ 1,903

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0
Definite-lived intangible asset charges	0	61,000,000
Impairment of indefinite-lived intangible assets	0	0
Amortization expense	$ 440,000,000	$ 446,000,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Definite-lived	$ 28,298	$ 29,004
Accumulated Amortization	(8,667)	(9,048)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-lived	603	604
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Definite-lived	16,968	16,944
Accumulated Amortization	(4,337)	(4,095)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Definite-lived	10,792	11,405
Accumulated Amortization	(4,059)	(4,570)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Definite-lived	464	570
Accumulated Amortization	(220)	(324)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Definite-lived	74	85
Accumulated Amortization	$ (51)	$ (59)

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jul. 26, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2020	$ 1,315
2021	1,738
2022	1,698
2023	1,630
2024	1,593
2025	$ 1,560

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018	Apr. 26, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	10.20%	8.70%
Certain tax adjustments	$ (30)	$ (29)
Net benefit related to measurement period adjustment related to U.S. Tax Reform	30	50
Charge related to recognition of prepaid tax expense		$ 21
Gross unrecognized tax benefits	1,900		$ 1,800
Accrued gross interest and penalties	186
Unrecognized tax benefits that would impact effective tax rate	$ 1,800

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Numerator:
Net income attributable to ordinary shareholders	$ 864	$ 1,075
Denominator:
Basic - weighted average shares outstanding (shares)	1,340.8	1,352.7
Effect of dilutive securities:
Employee stock options (shares)	6.9	8.4
Employee restricted stock units (shares)	3.5	3.6
Other (shares)	0.7	0.7
Diluted - weighted average shares outstanding (shares)	1,351.9	1,365.4
Basic earnings per share (usd per share)	$ 0.64	$ 0.79
Diluted earnings per share (usd per share)	$ 0.64	$ 0.79

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	3	6

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 61	$ 64
Income tax benefits	(10)	(11)
Total stock-based compensation expense, net of tax	51	53
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6	6
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	7	8
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	48	50
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	9	18
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	42	36
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 10	$ 10

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
U.S.
Net Periodic Benefit Cost
Service cost	$ 26	$ 27
Interest cost	32	33
Expected return on plan assets	(56)	(54)
Amortization of net actuarial loss	14	19
Net periodic benefit cost	16	25
Non-U.S.
Net Periodic Benefit Cost
Service cost	15	15
Interest cost	7	7
Expected return on plan assets	(15)	(14)
Amortization of net actuarial loss	3	3
Net periodic benefit cost	$ 10	$ 11

Leases - Balance Sheet Classif

Leases - Balance Sheet Classification and Amounts of Right-of-Use Asset and Lease Liability (Details) $ in Millions	Jul. 26, 2019USD ($)
Leases [Abstract]
Right-of-use assets	$ 948
Current liability	183
Non-current liability	$ 795

Leases - Weighted-Average Rema

Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details)	Jul. 26, 2019
Leases [Abstract]
Weighted-average remaining lease term	7 years 6 months
Weighted-average discount rate	3.00%

Leases - Components of Total O

Leases - Components of Total Operating Lease Cost (Details) $ in Millions	3 Months Ended
	Jul. 26, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 55
Short-term lease cost	11
Total operating lease cost	$ 66

Leases - Supplemental Cash Flo

Leases - Supplemental Cash Flow Information (Details) $ in Millions	3 Months Ended
	Jul. 26, 2019USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 57
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 49

Leases - Maturities of Operati

Leases - Maturities of Operating Leases (Details) $ in Millions	Jul. 26, 2019USD ($)
Leases [Abstract]
Remaining 2020	$ 152
2021	184
2022	153
2023	132
2024	111
Thereafter	432
Total expected lease payments	1,164
Less: Imputed interest	(186)
Total lease liability	$ 978

Leases - Minimum Payments Unde

Leases - Minimum Payments Under Non-Cancelable Operating Leases (Details) $ in Millions	Apr. 26, 2019USD ($)
Leases [Abstract]
2020	$ 216
2021	157
2022	103
2023	61
2024	34
Thereafter	81
Total minimum lease payments	$ 652

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Changes in AOCI (Details) - USD ($)		3 Months Ended
		Jul. 26, 2019	Jul. 27, 2018	Apr. 27, 2019	Apr. 28, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		$ 50,212,000,000	$ 50,822,000,000
Other comprehensive income (loss)		227,000,000	(584,000,000)
Cumulative effect of change in accounting principle	[1]			$ (33,000,000)
Ending balance		50,497,000,000	50,329,000,000
Unrealized (Loss) Gain on Investment Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(45,000,000)	(194,000,000)
Other comprehensive (loss) income before reclassifications		51,000,000	0
Reclassifications		5,000,000	0
Other comprehensive income (loss)		56,000,000	0
Cumulative effect of change in accounting principle					$ 47,000,000
Ending balance		11,000,000	(147,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)		(1,000,000)	0
Reclassifications, tax expense (benefit)		(1,000,000)	0
Cumulative Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(1,383,000,000)	(11,000,000)
Other comprehensive (loss) income before reclassifications		66,000,000	(824,000,000)
Reclassifications		0	0
Other comprehensive income (loss)		66,000,000	(824,000,000)
Cumulative effect of change in accounting principle					0
Ending balance		(1,317,000,000)	(835,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)		0	(5,000,000)
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(169,000,000)
Other comprehensive (loss) income before reclassifications		99,000,000
Reclassifications		0
Other comprehensive income (loss)		99,000,000
Ending balance		(70,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)		0
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(257,000,000)
Other comprehensive (loss) income before reclassifications			0
Reclassifications			0
Other comprehensive income (loss)			0
Cumulative effect of change in accounting principle					0
Ending balance			(257,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			0
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(1,308,000,000)	(1,117,000,000)
Other comprehensive (loss) income before reclassifications		0	0
Reclassifications		13,000,000	27,000,000
Other comprehensive income (loss)		13,000,000	27,000,000
Cumulative effect of change in accounting principle					0
Ending balance		(1,295,000,000)	(1,090,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)		0	0
Reclassifications, tax expense (benefit)		(3,000,000)	(5,000,000)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		194,000,000
Other comprehensive (loss) income before reclassifications		26,000,000
Reclassifications		(33,000,000)
Other comprehensive income (loss)		(7,000,000)
Ending balance		187,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)		1,000,000
Reclassifications, tax expense (benefit)		11,000,000
Unrealized (Loss) Gain on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(207,000,000)
Other comprehensive (loss) income before reclassifications			209,000,000
Reclassifications			4,000,000
Other comprehensive income (loss)			213,000,000
Cumulative effect of change in accounting principle					0
Ending balance			6,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			60,000,000
Reclassifications, tax expense (benefit)			(1,000,000)
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(2,711,000,000)	(1,786,000,000)
Other comprehensive (loss) income before reclassifications		242,000,000	(615,000,000)
Reclassifications		(15,000,000)	31,000,000
Other comprehensive income (loss)		227,000,000	(584,000,000)
Cumulative effect of change in accounting principle	[2]				$ 47,000,000
Ending balance		$ (2,484,000,000)	$ (2,323,000,000)
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter fiscal year 2020.
[2]	The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $ 47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Aug. 07, 2019claim	Nov. 28, 2018USD ($)	Dec. 14, 2011patent	Jun. 29, 2007	May 31, 2017claim	Jul. 26, 2019USD ($)subsidiarymanufacturerclaimlandfill	Apr. 29, 2016USD ($)claim	Apr. 26, 2019USD ($)
Loss Contingencies [Line Items]
Accrued litigation charges | $						$ 500		$ 500
Covidien
Loss Contingencies [Line Items]
Tax sharing percentage, parent				42.00%
Tax sharing percentage, former parent				27.00%
Tax sharing percentage, former affiliate				31.00%
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill						2
Number of landfills requiring capping | landfill						3
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of subsidiaries | subsidiary						2
Number of manufacturers | manufacturer						1
Settlement receivable | $							$ 121
Number of claims settled | claim					5,000		11,000
Number of pending claims | claim						15,800
Pelvic mesh | Product liability litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of claims settled | claim	15,400
Ethicon
Loss Contingencies [Line Items]
Patents infringed | patent			1
Patents not infringed upon | patent			6
Sasso
Loss Contingencies [Line Items]
Approximate amount of verdict returned against the Company | $		$ 112

Segment and Geographic Inform_3

Segment and Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Segment Reporting Information [Line Items]
Net sales	$ 7,493	$ 7,384
Income before Income Taxes by Reportable Segment
Segment operating profit	1,485	1,236
Interest expense	(609)	(242)
Amortization of intangible assets	(440)	(446)
Restructuring and associated costs	(47)	(62)
Certain litigation charges	(47)	(103)
Income (loss) before income taxes	977	1,180
Ireland
Segment Reporting Information [Line Items]
Net sales	20	22
United States
Segment Reporting Information [Line Items]
Net sales	3,918	3,864
Rest of world
Segment Reporting Information [Line Items]
Net sales	3,555	3,498
Total other countries, excluding Ireland
Segment Reporting Information [Line Items]
Net sales	7,473	7,362
Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	2,768	2,763
Segment Reconciling Items
Income before Income Taxes by Reportable Segment
Interest expense	(609)	(242)
Other non-operating income, net	101	186
Amortization of intangible assets	(440)	(446)
Corporate	(307)	(303)
Centralized distribution costs	(345)	(446)
Restructuring and associated costs	(124)	(113)
Acquisition-related items	(19)	(36)
Certain litigation charges	(47)	(103)
Exit of businesses	0	(80)
Debt tender premium and other charges	7	0
Medical device regulations	(8)	0
Cardiac and Vascular Group
Segment Reporting Information [Line Items]
Net sales	2,790	2,811
Cardiac and Vascular Group | United States
Segment Reporting Information [Line Items]
Net sales	1,361	1,389
Cardiac and Vascular Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	1,055	1,049
Minimally Invasive Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,100	2,052
Minimally Invasive Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	913	857
Minimally Invasive Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	771	776
Restorative Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,012	1,949
Restorative Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	1,338	1,294
Restorative Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	793	766
Diabetes Group
Segment Reporting Information [Line Items]
Net sales	592	572
Diabetes Group | United States
Segment Reporting Information [Line Items]
Net sales	306	324
Diabetes Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	$ 149	$ 172

Guarantor Financial Informati_3

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,493	$ 7,384
Costs and expenses:
Cost of products sold	2,366	2,204
Research and development expense	587	585
Selling, general, and administrative expense	2,543	2,597
Amortization of intangible assets	440	446
Restructuring charges, net	47	62
Certain litigation charges	47	103
Other operating expense (income), net	(22)	151
Operating profit (loss)	1,485	1,236
Other non-operating (income) expense, net	(101)	(186)
Interest expense	609	242
Equity in net (income) loss of subsidiaries	0	0
Income (loss) before income taxes	977	1,180
Income tax (benefit) provision	100	103
Net income (loss)	877	1,077
Net income attributable to noncontrolling interests	(13)	(2)
Net income (loss) attributable to Medtronic	864	1,075
Other comprehensive income (loss), net of tax	227	(584)
Comprehensive (income) loss attributable to noncontrolling interests	(13)	(2)
Comprehensive income attributable to Medtronic	1,091	491
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	(426)	(362)
Costs and expenses:
Cost of products sold	(311)	(237)
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	(89)	(101)
Operating profit (loss)	(26)	(24)
Other non-operating (income) expense, net	609	642
Interest expense	(609)	(642)
Equity in net (income) loss of subsidiaries	2,566	3,103
Income (loss) before income taxes	(2,592)	(3,127)
Income tax (benefit) provision	0	0
Net income (loss)	(2,592)	(3,127)
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	(2,592)	(3,127)
Other comprehensive income (loss), net of tax	(381)	1,695
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	(2,973)	(1,432)
Consolidating Adjustments | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	0	5
Operating profit (loss)	0	(5)
Other non-operating (income) expense, net	612	268
Interest expense	(612)	(268)
Equity in net (income) loss of subsidiaries	2,917	3,256
Income (loss) before income taxes	(2,917)	(3,261)
Income tax (benefit) provision	0	0
Net income (loss)	(2,917)	(3,261)
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	(2,917)	(3,261)
Other comprehensive income (loss), net of tax	(439)	1,208
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	(3,356)	(2,053)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	2	3
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	13	0
Operating profit (loss)	(15)	(3)
Other non-operating (income) expense, net	0	0
Interest expense	145	99
Equity in net (income) loss of subsidiaries	(1,022)	(1,175)
Income (loss) before income taxes	862	1,073
Income tax (benefit) provision	(2)	(2)
Net income (loss)	864	1,075
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	864	1,075
Other comprehensive income (loss), net of tax	227	(584)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	1,091	491
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	2	3
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	13	0
Operating profit (loss)	(15)	(3)
Other non-operating (income) expense, net	0	0
Interest expense	145	99
Equity in net (income) loss of subsidiaries	(1,022)	(1,175)
Income (loss) before income taxes	862	1,073
Income tax (benefit) provision	(2)	(2)
Net income (loss)	864	1,075
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	864	1,075
Other comprehensive income (loss), net of tax	227	(584)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	1,091	491
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	426	362
Costs and expenses:
Cost of products sold	326	273
Research and development expense	168	168
Selling, general, and administrative expense	378	366
Amortization of intangible assets	3	2
Restructuring charges, net	3	10
Certain litigation charges	5	78
Other operating expense (income), net	(439)	(259)
Operating profit (loss)	(18)	(276)
Other non-operating (income) expense, net	(61)	(160)
Interest expense	712	465
Equity in net (income) loss of subsidiaries	(610)	(814)
Income (loss) before income taxes	(59)	233
Income tax (benefit) provision	(129)	(104)
Net income (loss)	70	337
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	70	337
Other comprehensive income (loss), net of tax	46	(507)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	116	(170)
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	0	0
Operating profit (loss)	0	0
Other non-operating (income) expense, net	(63)	(11)
Interest expense	221	21
Equity in net (income) loss of subsidiaries	(968)	(972)
Income (loss) before income taxes	810	962
Income tax (benefit) provision	0	0
Net income (loss)	810	962
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	810	962
Other comprehensive income (loss), net of tax	84	(40)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	894	922
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	(7)	0
Operating profit (loss)	7	0
Other non-operating (income) expense, net	(245)	(164)
Interest expense	164	103
Equity in net (income) loss of subsidiaries	(934)	(1,114)
Income (loss) before income taxes	1,022	1,175
Income tax (benefit) provision	0	0
Net income (loss)	1,022	1,175
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	1,022	1,175
Other comprehensive income (loss), net of tax	227	(584)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	1,249	591
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	1
Amortization of intangible assets	0	0
Restructuring charges, net	0	0
Certain litigation charges	0	0
Other operating expense (income), net	(7)	0
Operating profit (loss)	7	(1)
Other non-operating (income) expense, net	(253)	(170)
Interest expense	165	103
Equity in net (income) loss of subsidiaries	(927)	(1,109)
Income (loss) before income taxes	1,022	1,175
Income tax (benefit) provision	0	0
Net income (loss)	1,022	1,175
Net income attributable to noncontrolling interests	0	0
Net income (loss) attributable to Medtronic	1,022	1,175
Other comprehensive income (loss), net of tax	227	(584)
Comprehensive (income) loss attributable to noncontrolling interests	0	0
Comprehensive income attributable to Medtronic	1,249	591
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,493	7,384
Costs and expenses:
Cost of products sold	2,351	2,168
Research and development expense	419	417
Selling, general, and administrative expense	2,163	2,228
Amortization of intangible assets	437	444
Restructuring charges, net	44	52
Certain litigation charges	42	25
Other operating expense (income), net	500	511
Operating profit (loss)	1,537	1,539
Other non-operating (income) expense, net	(404)	(504)
Interest expense	197	217
Equity in net (income) loss of subsidiaries	0	0
Income (loss) before income taxes	1,744	1,826
Income tax (benefit) provision	231	209
Net income (loss)	1,513	1,617
Net income attributable to noncontrolling interests	(13)	(2)
Net income (loss) attributable to Medtronic	1,500	1,615
Other comprehensive income (loss), net of tax	108	(604)
Comprehensive (income) loss attributable to noncontrolling interests	(13)	(2)
Comprehensive income attributable to Medtronic	1,608	1,011
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,493	7,384
Costs and expenses:
Cost of products sold	2,366	2,204
Research and development expense	587	585
Selling, general, and administrative expense	2,541	2,593
Amortization of intangible assets	440	446
Restructuring charges, net	47	62
Certain litigation charges	47	103
Other operating expense (income), net	(28)	146
Operating profit (loss)	1,493	1,245
Other non-operating (income) expense, net	(397)	(273)
Interest expense	690	287
Equity in net (income) loss of subsidiaries	0	0
Income (loss) before income taxes	1,200	1,231
Income tax (benefit) provision	102	105
Net income (loss)	1,098	1,126
Net income attributable to noncontrolling interests	(13)	(2)
Net income (loss) attributable to Medtronic	1,085	1,124
Other comprehensive income (loss), net of tax	128	(584)
Comprehensive (income) loss attributable to noncontrolling interests	(13)	(2)
Comprehensive income attributable to Medtronic	$ 1,213	$ 540

Guarantor Financial Informati_4

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jul. 26, 2019	Apr. 26, 2019	Jul. 27, 2018	Apr. 27, 2018
Current assets:
Cash and cash equivalents	$ 5,080	$ 4,393	$ 4,380	$ 3,669
Investments	5,603	5,455
Accounts receivable, net	5,894	6,222
Inventories, net	3,932	3,753
Intercompany receivable	0	0
Other current assets	2,196	2,144
Total current assets	22,705	21,967
Property, plant, and equipment, net	4,711	4,675
Goodwill	40,082	39,959
Other intangible assets, net	20,234	20,560
Tax assets	1,545	1,519
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,991	1,014
Total assets	91,268	89,694
Current liabilities:
Current debt obligations	1,458	838
Accounts payable	1,906	1,953
Intercompany payable	0	0
Accrued compensation	1,507	2,189
Accrued income taxes	500	567
Other accrued expenses	3,147	2,925
Total current liabilities	8,518	8,472
Long-term debt	24,804	24,486
Accrued compensation and retirement benefits	1,640	1,651
Accrued income taxes	2,873	2,838
Intercompany loans payable	0	0
Deferred tax liabilities	1,346	1,278
Other liabilities	1,590	757
Total liabilities	40,771	39,482
Shareholders’ equity	50,363	50,091
Noncontrolling interests	134	121
Total equity	50,497	50,212	50,329	50,822
Total liabilities and equity	91,268	89,694
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	(250)	(227)
Intercompany receivable	(40,678)	(28,623)
Other current assets	0	0
Total current assets	(40,928)	(28,850)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(204,018)	(200,493)
Intercompany loans receivable	(57,276)	(66,277)
Other assets	0	0
Total assets	(302,222)	(295,620)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(40,678)	(28,623)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	(40,678)	(28,623)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(57,276)	(66,277)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(97,954)	(94,900)
Shareholders’ equity	(204,268)	(200,720)
Noncontrolling interests	0	0
Total equity	(204,268)	(200,720)
Total liabilities and equity	(302,222)	(295,620)
Consolidating Adjustments | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	(11,151)	(8,626)
Other current assets	0	0
Total current assets	(11,151)	(8,626)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(187,929)	(167,560)
Intercompany loans receivable	(76,453)	(63,979)
Other assets	0	0
Total assets	(275,533)	(240,165)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(11,151)	(8,626)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	(11,151)	(8,626)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(76,453)	(63,979)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(87,604)	(72,605)
Shareholders’ equity	(187,929)	(167,560)
Noncontrolling interests	0	0
Total equity	(187,929)	(167,560)
Total liabilities and equity	(275,533)	(240,165)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	80	40
Other current assets	16	10
Total current assets	96	50
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	65,549	64,352
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	68,645	67,402
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	12	3
Accrued income taxes	0	0
Other accrued expenses	20	20
Total current liabilities	32	23
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	18,240	17,278
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	18,282	17,311
Shareholders’ equity	50,363	50,091
Noncontrolling interests	0	0
Total equity	50,363	50,091
Total liabilities and equity	68,645	67,402
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	80	40
Other current assets	16	10
Total current assets	96	50
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	65,549	64,352
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	68,645	67,402
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	12	3
Accrued income taxes	0	0
Other accrued expenses	20	20
Total current liabilities	32	23
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	18,240	17,278
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	18,282	17,311
Shareholders’ equity	50,363	50,091
Noncontrolling interests	0	0
Total equity	50,363	50,091
Total liabilities and equity	68,645	67,402
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	15	18	24	20
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	184	188
Intercompany receivable	9,837	9,407
Other current assets	212	190
Total current assets	10,248	9,803
Property, plant, and equipment, net	1,508	1,480
Goodwill	2,009	2,009
Other intangible assets, net	96	99
Tax assets	494	568
Investment in subsidiaries	72,421	71,129
Intercompany loans receivable	21	21
Other assets	308	216
Total assets	87,105	85,325
Current liabilities:
Current debt obligations	1,033	500
Accounts payable	492	481
Intercompany payable	21,093	11,971
Accrued compensation	532	913
Accrued income taxes	0	0
Other accrued expenses	467	331
Total current liabilities	23,617	14,196
Long-term debt	9,780	14,418
Accrued compensation and retirement benefits	1,070	1,069
Accrued income taxes	709	692
Intercompany loans payable	9,011	12,613
Deferred tax liabilities	0	0
Other liabilities	223	133
Total liabilities	44,410	43,121
Shareholders’ equity	42,695	42,204
Noncontrolling interests	0	0
Total equity	42,695	42,204
Total liabilities and equity	87,105	85,325
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	0	0
Other current assets	0	0
Total current assets	0	0
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	57,719	39,557
Intercompany loans receivable	3,989	4,119
Other assets	0	0
Total assets	61,708	43,676
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	1,316	1,308
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	8	11
Total current liabilities	1,324	1,319
Long-term debt	1,311	1,354
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	27,127	9,320
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	29,762	11,993
Shareholders’ equity	31,946	31,683
Noncontrolling interests	0	0
Total equity	31,946	31,683
Total liabilities and equity	61,708	43,676
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	93	1	390	1
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	5	6
Other current assets	3	3
Total current assets	101	10
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	66,048	65,012
Intercompany loans receivable	29,017	27,858
Other assets	0	0
Total assets	95,166	92,880
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	9,662	7,200
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	39	53
Total current liabilities	9,701	7,253
Long-term debt	13,601	8,621
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	13,320	19,682
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	36,622	35,556
Shareholders’ equity	58,544	57,324
Noncontrolling interests	0	0
Total equity	58,544	57,324
Total liabilities and equity	95,166	92,880
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	93	1	390	1
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	1,381	1,374
Other current assets	3	3
Total current assets	1,477	1,378
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	64,661	63,651
Intercompany loans receivable	29,017	27,858
Other assets	0	0
Total assets	95,155	92,887
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	9,662	7,199
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	44	60
Total current liabilities	9,706	7,259
Long-term debt	13,601	8,621
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	13,320	19,682
Deferred tax liabilities	0	0
Other liabilities	1	1
Total liabilities	36,628	35,563
Shareholders’ equity	58,527	57,324
Noncontrolling interests	0	0
Total equity	58,527	57,324
Total liabilities and equity	95,155	92,887
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	4,972	4,374	3,966	3,648
Investments	5,603	5,455
Accounts receivable, net	5,894	6,222
Inventories, net	3,998	3,792
Intercompany receivable	30,756	19,170
Other current assets	1,965	1,941
Total current assets	53,188	40,954
Property, plant, and equipment, net	3,203	3,195
Goodwill	38,073	37,950
Other intangible assets, net	20,138	20,461
Tax assets	1,051	951
Investment in subsidiaries	0	0
Intercompany loans receivable	25,238	35,398
Other assets	1,683	798
Total assets	142,574	139,707
Current liabilities:
Current debt obligations	425	338
Accounts payable	1,414	1,472
Intercompany payable	9,923	9,452
Accrued compensation	963	1,273
Accrued income taxes	500	567
Other accrued expenses	2,621	2,521
Total current liabilities	15,846	15,623
Long-term debt	1,423	1,447
Accrued compensation and retirement benefits	570	582
Accrued income taxes	2,154	2,136
Intercompany loans payable	16,705	16,704
Deferred tax liabilities	1,346	1,278
Other liabilities	1,367	624
Total liabilities	39,411	38,394
Shareholders’ equity	103,029	101,192
Noncontrolling interests	134	121
Total equity	103,163	101,313
Total liabilities and equity	142,574	139,707
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	4,987	4,392	$ 3,990	$ 3,668
Investments	5,603	5,455
Accounts receivable, net	5,894	6,222
Inventories, net	3,932	3,753
Intercompany receivable	9,690	7,212
Other current assets	2,177	2,131
Total current assets	32,283	29,165
Property, plant, and equipment, net	4,711	4,675
Goodwill	40,082	39,959
Other intangible assets, net	20,234	20,560
Tax assets	1,545	1,519
Investment in subsidiaries	0	0
Intercompany loans receivable	40,447	29,002
Other assets	1,991	1,014
Total assets	141,293	125,894
Current liabilities:
Current debt obligations	1,458	838
Accounts payable	1,906	1,953
Intercompany payable	173	119
Accrued compensation	1,495	2,186
Accrued income taxes	500	567
Other accrued expenses	3,075	2,834
Total current liabilities	8,607	8,497
Long-term debt	9,892	14,511
Accrued compensation and retirement benefits	1,640	1,651
Accrued income taxes	2,863	2,828
Intercompany loans payable	17,766	17,699
Deferred tax liabilities	1,346	1,278
Other liabilities	1,589	756
Total liabilities	43,703	47,220
Shareholders’ equity	97,456	78,553
Noncontrolling interests	134	121
Total equity	97,590	78,674
Total liabilities and equity	$ 141,293	$ 125,894

Guarantor Financial Informati_5

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 26, 2019	Jul. 27, 2018
Operating Activities:
Net cash provided by (used in) operating activities	$ 1,510	$ 1,702
Investing Activities:
Acquisitions, net of cash acquired	(145)	(104)
Additions to property, plant, and equipment	(301)	(291)
Purchases of investments	(1,669)	(982)
Sales and maturities of investments	1,569	2,020
Capital contribution paid	0	0
Other investing activities	(5)	0
Net cash (used in) provided by investing activities	(551)	643
Financing Activities:
Change in current debt obligations, net	88	(505)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(5,035)	(12)
Dividends to shareholders	(724)	(677)
Issuance of ordinary shares	210	450
Repurchase of ordinary shares	(333)	(824)
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	0	0
Other financing activities	(47)	(5)
Net cash provided by (used in) financing activities	(274)	(1,573)
Effect of exchange rate changes on cash and cash equivalents	2	(61)
Net change in cash and cash equivalents	687	711
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	5,080	4,380
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		32
Other investing activities	0
Net cash (used in) provided by investing activities	0	32
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received		(32)
Other financing activities	0	0
Net cash provided by (used in) financing activities	0	(32)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	6	185
Other investing activities	0
Net cash (used in) provided by investing activities	6	185
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	(6)	(185)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(6)	(185)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(115)	(6)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		0
Other investing activities	0
Net cash (used in) provided by investing activities	0	0
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	(724)	(677)
Issuance of ordinary shares	210	450
Repurchase of ordinary shares	(333)	(824)
Net intercompany loan borrowings (repayments)	962	1,057
Capital contribution received		0
Other financing activities	0	0
Net cash provided by (used in) financing activities	115	6
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(115)	(6)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	0
Other investing activities	0
Net cash (used in) provided by investing activities	0	0
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	(724)	(677)
Issuance of ordinary shares	210	450
Repurchase of ordinary shares	(333)	(824)
Net intercompany loan borrowings (repayments)	962	1,057
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	115	6
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(803)	(387)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	(74)	(49)
Purchases of investments	0	0
Sales and maturities of investments	0	76
Capital contribution paid		(32)
Other investing activities	0
Net cash (used in) provided by investing activities	(74)	(5)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	(4,463)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	5,337	396
Capital contribution received		0
Other financing activities	0	0
Net cash provided by (used in) financing activities	874	396
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(3)	4
Cash and cash equivalents at beginning of period	18	20
Cash and cash equivalents at end of period	15	24
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(161)	(24)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(6)	(185)
Other investing activities	0
Net cash (used in) provided by investing activities	(6)	(185)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	(44)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	211	209
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	167	209
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	150	72
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid		0
Other investing activities	(5)
Net cash (used in) provided by investing activities	(5)	0
Financing Activities:
Change in current debt obligations, net	0	(472)
Issuance of long-term debt	5,567
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,058)	789
Capital contribution received		0
Other financing activities	(47)	0
Net cash provided by (used in) financing activities	(53)	317
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	92	389
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	93	390
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	157	77
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	0
Other investing activities	(5)
Net cash (used in) provided by investing activities	(5)	0
Financing Activities:
Change in current debt obligations, net	0	(473)
Issuance of long-term debt	5,567
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,065)	785
Capital contribution received	0	0
Other financing activities	(47)	0
Net cash provided by (used in) financing activities	(60)	312
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	92	389
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	93	390
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	2,278	2,023
Investing Activities:
Acquisitions, net of cash acquired	(145)	(104)
Additions to property, plant, and equipment	(227)	(242)
Purchases of investments	(1,669)	(982)
Sales and maturities of investments	1,569	1,944
Capital contribution paid		0
Other investing activities	0
Net cash (used in) provided by investing activities	(472)	616
Financing Activities:
Change in current debt obligations, net	88	(33)
Issuance of long-term debt	0
Payments on long-term debt	(57)	(12)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(1,241)	(2,242)
Capital contribution received		32
Other financing activities	0	(5)
Net cash provided by (used in) financing activities	(1,210)	(2,260)
Effect of exchange rate changes on cash and cash equivalents	2	(61)
Net change in cash and cash equivalents	598	318
Cash and cash equivalents at beginning of period	4,374	3,648
Cash and cash equivalents at end of period	4,972	3,966
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	1,629	1,655
Investing Activities:
Acquisitions, net of cash acquired	(145)	(104)
Additions to property, plant, and equipment	(301)	(291)
Purchases of investments	(1,669)	(982)
Sales and maturities of investments	1,569	2,020
Capital contribution paid	0	0
Other investing activities	0
Net cash (used in) provided by investing activities	(546)	643
Financing Activities:
Change in current debt obligations, net	88	(32)
Issuance of long-term debt	0
Payments on long-term debt	(4,476)	(12)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	3,892	(2,051)
Capital contribution received	6	185
Other financing activities	0	(5)
Net cash provided by (used in) financing activities	(490)	(1,915)
Effect of exchange rate changes on cash and cash equivalents	2	(61)
Net change in cash and cash equivalents	595	322
Cash and cash equivalents at beginning of period	4,392	3,668
Cash and cash equivalents at end of period	$ 4,987	$ 3,990

Uncategorized Items - mdt-2020q

Label	Element	Value
Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (33,000,000)	[1]
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(47,000,000)	[2]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (33,000,000)	[1]
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter fiscal year 2020.
[2]	The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $ 47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.